PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C07H 21/00 | A2

(11) International Publication Number: **WO 99/16780**

(43) International Publication Date: 8 April 1999 (08.04.99)

(21) International Application Number: PCT/BE98/00141

(22) International Filing Date: 28 September 1998 (28.09.98)

(30) Priority Data:
97870146.4 26 September 1997 (26.09.97) EP

(71) Applicants *(for all designated States except US)*: UNIVERSITE CATHOLIQUE DE LOUVAIN [BE/BE]; Halles Universitaires, Place de l'Université 1, B–1348 Louvain–la–Neuve (BE). MINISTERE DE LA DEFENSE NATIONALE [BE/BE]; Etat Major Général, JSM – R & T, Quartier Reine Elisabeth, Rue d'Evere 1, B–1140 Bruxelles (BE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: VANNUFFEL, Pascal [BE/BE]; Rue de la Basse Egypte 138, B–7133 Buvrinnes (BE). GALA, Jean–Luc [BE/BE]; Rue Grand Chemin Communal 6, B–5380 Fernelmont (BE).

(74) Agents: VAN MALDEREN, Eric et al.; Office Van Malderen, Place Reine Fabiola 6/1, B–1083 Bruxelles (BE).

(81) Designated States: CA, JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).

Published
Without international search report and to be republished upon receipt of that report.

(54) Title: GENETIC SEQUENCES, DIAGNOSTIC AND/OR QUANTIFICATION METHODS AND DEVICES FOR THE IDENTIFICATION OF *STAPHYLOCOCCI* STRAINS

(57) Abstract

The present invention is related to oligonucleotides for the specific identification of *Staphylococci* species which nucleotide sequence has between 15 and 350 base pairs, preferably between 15 and 45 base pairs, obtained from the "consensus" *femA* nucleotide sequence (CNS) of the figure or its complementary strand. The present invention is also related to a method and a diagnostic device using said oligonucleotide for the identification of various types of *Staphylococci* species strains.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

GENETIC SEQUENCES, DIAGNOSTIC AND/OR QUANTIFICATION METHODS AND DEVICES FOR THE IDENTIFICATION OF *STAPHYLOCOCCI* STRAINS

Field of the invention

The present invention refers to new genetic sequences, diagnostic and/or quantification methods and devices using said sequences for the identification of various types of *Staphylococci* strains as well as the therapeutical aspects of said genetic sequences.

Background of the invention

Increasing incidence of nosocomial infections by multiresistant bacteria (even to antibiotics like vancomycin) is a world-wide concern. Methicillin-resistant coagulase-negative *Staphylococci* (MR-CNS) and *S. aureus* (MRSA) express a high level cross-resistance to all ß-lactam antibiotics (Ryffel et al. (1990), Refsahl et al. (1992)). They have an additional low-affinity penicillin-building protein, PBP2a (PBP2'), encoded by the *mecA* gene. The *mecA* determinant is found in all multiresistant staphylococcal species (Chackbart et al. (1989), Suzuki et al. (1992), Vannuffel et al. (1995)) and is highly conserved among the different species (Ryffel et al. (1990)).

Several other chromosomal sites, in which transposon inactivation reduces the level of ß-lactam resistance, have been identified in *S. aureus* (SA) (Hiramatsu (1992), Berger-Bächi et al. (1992), de Lancastre et al. (1994)). The appropriate functioning of these regulator genes rather than the quantity of PBP2a determines the minimal inhibitory concentration value and homogeneous expression of resistance of staphylococcal isolates (Ryffel et al. (1994), de Lancastre et al. (1994)).

The *femA-femB* operon, initially identified in *S. aureus*, is one of those genetic factors essential for methicillin resistance (Berger-Bächi et al. (1989)). It is involved in the formation of the characteristic pentaglycine side chain of the SA peptidoglycan (Stranden et al. (1997)). Unlike other regulatory genes, *femA* was shown to retain a strong conservation over time in clinical isolates of MRSA, hence confirming its key role in cell wall metabolism and methicillin resistance (Hurlimann-Dalel et al. (1992)). In contrast to *mecA*, *femA-femB* is present both in the genome of resistant and susceptible SA strains (Unal et al. (1992), Vannuffel et al. (1995)).

Often, identification of the *Staphylococci* is limited to a rapid screening test for *S. aureus*, and non-*S. aureus* isolates are simply reported as coagulase-negative *Staphylococci*. In fact, these bacteria isolates include a variety of species and many different strains (Kleeman et al. (1993)). There is little epidemiological information related to the acquisition and spread of these organisms. This is potentially due to the lack of an easy and accurate way to identify species and to provide clinically timely informations.

Several molecular assays designed for detecting *femA* in SA failed to amplify an homologous sequence in coagulase-negative *Staphylococci* (Kizaki et al. (1994), Vannuffel et al. (1995)). Nevertheless, low-stringency heterologous hybridisation analysis suggested the presence of such a structurally related gene in *S. epidermidis* (SE) (Unal et al. (1992)).

These data were followed by complete identification and sequence analysis of the *femA* and *femB* open reading frames in *S. epidermidis* (Alborn et al. (1996)). Intra- and interspecies relatedness of these genes and conservation of genomic organisation are therefore consistent with gene duplication of one of these genes in an ancestral organism and the possibility of *femA* phylogenetic conservation in all staphylococcal species (Alborn et al. (1996)).

The complete genetic sequence of the *femA* gene de *S. epidermidis*, the protein encoded by the *femA* gene (*FemA*) and vectors and micro-organisms comprising genes encoding the *FemA* protein are described in the US patent 5,587,307.

Aims of the invention

The present invention aims to provide new genetic sequences, methods and devices for the improvement of the identification and/or the quantification of various types of *Staphylococci* strains through their *femA*-like determinants, which allow by a rapid screening their epidemiological study.

Another aim of the invention is to identify similar genetic sequences which may exist in known or not

known *Staphylococci* species or other gram-positive bacterial strains.

A last aim of the present invention is to provide new sequences encoding *femA* proteins of *Staphylococci* species, their *femA* proteins, vector(s) comprising said nucleotide sequences and cell (s) transformed by said vector(s) for possible therapeutical applications.

Summary of the invention

The Inventors have identified new DNA and amino acid sequences from new strains of *Staphylococcus hominis*, *Staphylococcus saprophyticus* and *Staphylococcus haemolyticus*. Said new nucleotide sequences allow an alignment of these new sequences with the *femA* gene from *Staphylococci* previously described (*S. aureus*, *S. epidermidis* and *S. saprophyticus*). By the alignment of more than 2 sequences, preferably more than 4 sequences, the Inventors have identified for the first time a consensus *femA* sequence useful for molecular genotyping of different *Staphylococci* species which was not possible previously, when only few *femA* sequences of *Staphylococci* strains were known.

Therefore, a first aspect of the present invention is related to the "consensus" nucleotide sequence as represented in the enclosed Figure 3. With said "consensus" nucleotide sequence, the Inventors were able to provide oligonucleotides (such as primers or probes) which can be used for the genetic amplification, the identification and/or quantification of various *femA* sequences which are specific of known or unknown *Staphylococci* species.

The *femA* sequence is known to be involved with the biosynthesis of glycin-containing cross-bridges of the peptidoglycan and the peptidoglycan organisation is also known to be well conserved among various *Staphylococci* species and possibly among other gram-positive bacteria.

Therefore, it is also possible to use the new "consensus" *femA* sequence and said new oligonucleotides extrapolated from the alignment of the sequences presented in Figure 3, for the molecular genotyping of other *Staphylococci* species and possibly other gram-positive bacteria. It is also known that the *femA* sequence is similar to the femB sequence. Therefore, these oligonucleotides could also be used for the molecular genotyping of femB genes of different *Staphylococci* species or other gram-positive bacteria.

Another aspect of the present invention concerns the possible therapeutical uses of new *femA* nucleotide sequences isolated from the strains *S. hominis*, *S. saprophyticus*, *S. haemolyticus*, *S. lugdunensis*, *S. xylosus*, *S. capitis*, *S. schleiferi* and *S. sciuri* having a nucleotide or amino acid sequence which presents more than 85%, preferably more than 90% homology or 100% homology with the genetic sequences presented in the Figures 6 to 13, their complementary strand and functional variants thereof. Functional variants of said amino acid sequences are peptides which contain one or more modifications to the primary amino acids sequence and retain the activity of the complete and wild type *femA* molecule. Variants of the peptide are obtained by nucleotidic sequences which differ from the above-identified described sequences by a degeneration of their genetic code or are sequences which hybridise with said sequences or their complementary

strand, preferably under stringent conditions such as the ones described in the document Sambrook et al., §§ 9.47-9.51 in *Molecular Cloning : A Laboratory Manual*, Cold Spring Harbor, Laboratory Press, Cold Spring Harbor, New York (1989).

A further aspect of the present invention concerns the recombinant vector (i.e. constructions into which the sequence of the invention may be inserted for transport in different genetic environments and for expression in a host cell, such as a phagemide, a virus, a plasmid, a cationic vesicle, a liposome, etc.) comprising said nucleotide sequences and their complementary strands, or the corresponding RNA sequences, possibly linked to one or more regulatory sequences or markers (resistance to antibiotics, enzyme coding sequences, ...) active into a cell.

Similarly, the nucleic acid sequence according to the invention may be obtained by synthetic methodology well known by the person skilled in the art, such as the one described by Brown et al. ("Method of Enzymology", Acad. Press, New-York, No. 68 pp. 109-151 (1979)) or by conventional DNA synthesising apparatus such as the applied biosystem model 380A or 380B DNA synthesiser.

Other aspects of the present invention concern the recombinant host (prokaryotic) cell transformed by said vector and the purified (possibly recombinant) proteins or peptides encoded by said nucleic acid sequences, possibly linked to a carrier molecule such as BSA and obtained by said cells. Said recombinant proteins or peptides could be obtained by genetic engineering or could be obtained by synthesis (see US patent 5,587,307

incorporated herein by reference) and may comprise residues enhancing their stability (resistance to hydrolysis by proteases, etc.) such as the one described by Nachman et al. (*Regul. Pept. Vol. 57*, pp. 359-370 (1995)).

A preferred vector for expression in a E. coli host cell is derived from the E. coli plasmid pET-11A available from Novagen Inc. (Catalogue No. 69436-A). The transformation technique used with the above-identified vector has been described in the US Patent 5587307.

A further aspect of the present invention concerns the inhibitor (used to possibly treat (with addition of antibiotics) antibiotics resistance bacteria) directed against said proteins, peptides or nucleic acid molecules. Advantageously, said inhibitor is a antibody, preferably a monoclonal antibody, or an antisense nucleotide molecule, such as a ribozyme, which could be present in a vector in order to block the expression of said *femA* nucleotide sequences.

A last aspect of the present invention concerns the pharmaceutical composition, preferably a vaccine, against *Staphylococci* infections in an animal, including a human, comprising a pharmaceutically acceptable carrier and a sufficient amount of an active compound selected from the group consisting of said nucleic acid molecules, vectors, recombinant host cells transformed by said vector(s), inhibitors (directed against said proteins, peptides or nucleic acid molecules) and a mixture thereof.

Another aspect of the present invention concerns oligonucleotides which are (DNA) sequences having between 15 and 350 base pairs, preferably between 17 and 250 base pairs (such as primers or probes) obtained from the consensus sequence of Figure 3 or its complementary

strand. Preferably, said oligonucleotides are primers having between 15 and 45 base pairs, more preferably between 17 and 25 base pairs.

According to a first embodiment of the present invention, said oligonucleotide is a primer having between 15 and 45 base pairs, which presents more than 60%, advantageously more than 70%, preferably more than 80%, more specifically more than 90% homology with (fragments of) the "consensus" *femA* nucleotide sequence (CNS) identified in the Figure 3.

Therefore, the oligonucleotides according to the invention are new sequences or preferred fragments of known sequences of *S. aureus*, *S. epidermidis* or *S. simulans* but not the complete wild type known *femA* nucleotide sequence.

Preferably, the oligonucleotide according to the invention is selected from the group consisting of the following nucleotide sequences :

- ANAATGAANTTTACNAATTTNACNGCNANAGANTT
  and more particularly *femS1* TAATGAAGTTTACAAAATTT or *femS2* TAATGAAGTTTACNAAATTT
- ATGNCNNANAGNCATTTNACNCANA
  and more particularly *femU1* ("universal" sequence sense of the multiplex PCR): TGCCATATAGTCATTTACGC
- TAGTNGGNATNAANAANAANNATAANGANGTNATTGC
- GTNCCNGTNATGAAAANTNTTNAANTANTTTTATTC
- AATGCNGGNNANGATTGG
- GNAANNGNAANACNAAAAAAGTNNANAANAATGGNGTNAAAGT
  and more particularly *fsq1S* (et *1AS*) : AAAAAGTTCAAAAAATGG and *fsq2S* (and *2AS*) : AAAAAGTACAAAAAATGG
- AAGANGANNTNCCNATNTTNNGNTCATTNATGGANGATAC

- TATATNNANTTTGATGANTA
- AANGANATNGANAAANGNCCNGANAANAAAAA

and more particularly *fsq3S* (and *3AS*) : AAAGATATTGAAAAACGA, *fsq4S* (and *4AS*) : AAAGATATTGAAAAGAGACC, *fsq5S* (and *5AS*) : AAAGATATCGAGAAAGAC and *fsq6S* (and *6AS*) : AAAGACATCGACAAGCGT.

- ANCATGGNAANGAATTACCNAT

and more particularly *fem1* (primer for the production of a probe and of marked amplicons for reverse hybridisation experiment) : GAACATGGTAATGAATTAC

- AATCCNTNTGAAGTNGTNTANTANGCNGGTGG
- AGNTATGCNNTNCAATGGNNNATGATTAANTATGC
- TTTANNGANGANGCNGAAGATGNNGGNGTNNTNAANTTNAAAAA

and more particularly *fem3bio* (primer for the production of a probe and of marked amplicons for reverse hybridisation experiment) : TTTACTGAAGATGCTGAAGA

- GTTGGNGANTTNNTNAAACC

and more particularly *fem2* (primer for the production of a probe and of marked amplicons for reverse hybridisation experiment) : GTTGGTGACTTTATTAAACC

- ATGAAATTTACAGAGTTAA (= *femAS1*)

Said primer(s) will be designated hereafter as "universal primer(s)".

A further aspect of the present invention concerns the oligonucleotide being either a primer or a probe as above-described, having between 15 and 350 base pairs, preferably between 17 and 250 base pairs, or a primer having between 15 and 45 base pairs, more preferably between 17 and 25 base pairs, which will be designated

hereafter as "specific primer(s)", having a nucleotide sequence which presents less than 50%, advantageously less than 40%, preferably less than 30%, more specifically less than 20% homology with (fragments of) the "consensus" *femA* nucleotide sequence (CNS) identified in the Figure 3 and with another *femA nucleotide* sequence specific for other *Staphylococci* strains.

Advantageously, said "specific primer" is selected from the group consisting of the following nucleotide sequences :

- ACAGCAGATGACATCATT
- TAATGAAAGAAATGTGCTTA
- ACACAACTTCAATTAGAAC
- AGTATTAGCAAATGCGG
- ATGCATATTTTCCGTAA
- CAGCAGATGACATCATT
- CATCTAAAGATATATTAAATGGA
- AGTATTAGCAAATGCGGGTCAC
- CAACACAACTTCAATTAGAA

The oligonucleotides according to the invention are selected according to their physiochemical properties in order to avoid cross-hybridisation between themselves. Said primers are not complementary to each other and they contain a similar percentage of bases GC.

Said oligonucleotides are used in an identification and/or quantification method of one or more *Staphylococcus* species and possibly other gram-positive bacteria.

Therefore, another aspect of the present invention is related to an identification and/or

quantification method of a *Staphylococci* species which may present resistance to one or more antibiotic(s), and is possibly combined with a method for the identification of a resistance to antibiotics, especially β-lactam antibiotics, (for instance through the identification of a variant of the *mecA* gene as described by Vannuffel et al. (1998)).

The method for the detection, the identification and/or the quantification of a bacteria, preferably a staphylococcal species, comprises the steps of :

- obtaining a nucleotide sequence from said bacteria present in a sample, preferably a biological body sample obtained from a patient such as blood, serum, dialyse liquid or cerebrospinal liquid, or from any other bacteriological growth medium,
- possibly purifying said nucleotide sequence from possible contaminants,
- possibly amplifying by known genetic amplification techniques said nucleotide sequence with one or more universal oligonucleotide(s) (universal primer(s)) according to the invention, and
- identifying the specific gram-positive bacteria species, preferably the specific *Staphylocossi* species :
    - by a comparative measure of the length of the (possibly amplified) nucleotide sequence or
    - by reverse hybridisation of the (possibly amplified) nucleotide sequence with one or more specific oligonucleotide(s) (specific probe(s) or primer(s)) according to the invention which are specific of said bacteria, said oligonucleotide(s) being preferably immobilised on a solid support.

The comparative measure of the length of a possibly amplified nucleotide sequences can be performed by the analysis of their migration (compared with a known ladder) upon an electrophoresis gel.

Preferably, the genetic amplification technique is selected from the group consisting of PCR (US patent 4,965,188), LCR (Landgren et al., *Sciences*, 241, pp. 1077-1080 (1988)), NASBA (Kievits et al., *J. Virol. Methods*, 35, pp. 273-286 (1991)), CPR (patent WO95/14106) or ICR.

The specific detection of the possibly amplified nucleotide sequences can be obtained by the person skilled in the art by using known specific gel electrophoresis techniques, in situ hybridisation, hybridisation on solid support, in solution, on dot blot, by Northern blot or Southern blot hybridisation, etc.

Advantageously, the probes which are specific of the bacteria are immobilised on a solid support according to the method described in the international patent application WO98/11253 incorporated herein by reference.

Said specific oligonucleotides (probes or "elongated" primers) have a length comprised between 50 and 350 base pairs, preferably between 120 and 250 base pairs, and are fixed to the solid support by a terminal 5' phosphate upon an amine function of the solid support by carbodiimide reaction (as described in the document WO98/11253 incorporated herein by reference).

The solid support can be selected from the group consisting of cellulose or nylon filters, plastic supports such as 96-well microtiter plates, microbeads,

preferably magnetic microbeads, or any other support suitable for the fixation of a nucleotide sequence.

The method according to the invention can be advantageously combined with another specific detection step of a possible resistance to antibiotics, especially β-lactam antibiotics (for instance through the identification by the above-described technique of variants of the *mecA* gene as described by Vannuffel et al. (1998)).

The present invention concerns also a diagnostic and/or quantification device or kit for the identification and/or the quantification of a *Staphylococcus* species or other gram-positive bacteria, comprising the oligonucleotides according to the invention and possibly all the media necessary for the identification of a (possibly amplified) nucleotide sequence of said bacteria through any one of the above-described methods.

Advantageously, the method and device according to the invention are adapted for the quantification of said *Staphylococci* strains by the use of a "internal or external standard sequence", preferably the one described in the patent application WO98/11253 incorporated herein by reference.

Therefore, according to a first embodiment of the present invention, the nucleic acid sequence from a *Staphylococcus* species, for instance *Staphylococcus aureus*, is amplified by a "universal primer" and by a "specific primer" which is specific for *S. aureus*. The identification of *S. aureus* will be obtained upon an agarose electrophoresis gel wherein the amplified nucleotide sequence (shorter than the amplified nucleotide sequence of another *Staphylococci* species such as *S. epidermidis*) and identified by the use of a comparative ladder.

According to another embodiment of the present invention, a *Staphylococcus* species (such as *S. aureus*) is identified by reverse hybridisation of the amplified nucleotide sequence with a probe which is specific of said bacteria and which is immobilised on a solid support such as filter.

The present invention will be described in details in the following non-limiting examples, in reference to the Figures described hereafter.

Short description of the drawings

The Figure 1 represents 5 partially overlapping fragments of the *femA* genes from *S. hominis*, *S. saprophyticus* and *S. haemolyticus* obtained by PCR amplification.

The Figure 2 represents the alignment of the nucleotide sequences of *femA* genes from *S. hominis*, *S. saprophyticus*, *S. aureus*, *S. epidermidis* and *S. haemolyticus*.

The Figure 3 represents the consensus sequence according to the invention.

The Figure 4 represents the result of differential diagnosis between different strains of *Staphylococci* by reverse hybridisation.

The Figure 5 represents amplification of CNS species under universal conditions.

Figures 6 to 13 represent the complete *femA* wild type genetic sequence of the strains *S. hominis*, *S. saprophyticus*, *S. haemolyticus*, *S. lugdunensis*, *S. xylosus*, *S. capitis*, *S. schleiferi* and *S. sciuri*.

Examples

Example 1 : Sequencing strategy

Fragments of the *femA* genes from S. *hominis* and S. *saprophyticus* have been obtained by PCR amplification, in low stringency annealing conditions. Primers used for amplification are matching the potentially conserved regions and have been designed according to sequences homologies between *S. aureus*, *S. sapropyticus* and *S. epidermidis femA* nucleotide sequences. For both *S. hominis* and *S. saprophytiçus* species, 5 partially overlapping fragments have been synthesised allowing the sequencing of the entire *femA* genes (Fig. 1).

Example 2 : Identification of a consensus sequence

Alignment of the nucleotide sequences of *femA* genes from *S. hominis* and *S. saprophyticus* as well as with *femA* genes sequenced to date from *S. aureus* (GenBank accession number M23918), *S. epidermidis* (GenBank accession number U23713) and *S. haemolyticus* is presented in Fig. 3 and has allowed to propose a "consensus" *femA* nucleotide sequence (CNS) whose genomic organisation displays highly conserved regions flanked by variable ones. On this basis, interspecies phylogenetic variations could be exploited to design genotyping strategies for species-specific identification of *Staphylococci*. The "consensus" sequence is therefore a powerful molecular tool for specific diagnostic of staphylococcal infections.

Example 3 : Sequencing of other staphylococcal *femA* genes

The consensus sequence can be exploited for designing universal primers allowing the production, under permissive annealing conditions, of overlapping PCR

products whose sequencing will identify the entire *femA* sequence.

Example 4 : Differential diagnosis between *S. aureus, S. epidermidis, S. hominis* and *S. saprophyticus* by reverse hybridisation

The Inventors have set up a reverse hybridisation assay for rapid and combined identification of the most clinically relevant *Staphylococci* species, and their *mecA* status. Two sets of primers, chosen in a conserved domain of the consensus sequence (*bioU1-bioU3* and *fem1-fem3bio*), amplifying a 286 and bio-220 bp fragments, respectively) were synthesised. Species-specificity of *femA* amplicons was insured by the genomic variability between the conserved regions. *FemA* probes were immobilised on nylon strips. Hybridisation was performed with biotinylated *femA* PCR fragments from the strain of interest. The strategy was first assessed with ATCC strains (*S. aureus, S. epidermidis, S. hominis* and *S. saprophyticus*) (Fig. 4). Specificity was identified by standard methods. Accuracy was 100% for species identification.

Example 5 : Differential diagnosis between staphylococcal species

This assay is able to identify any staphylococcal species if following requirements are fulfilled :

- primers *fem1, fem2* and *fem3bio* are universal for *Staphylococci;*
- there is a wide enough phylogenetic variation between any CNS species to promote a specific hybridisation.

The first requirement is fulfilled for, i.e., *S. haemolyticus*, *S. capitis*, *S. cohnii*, *S. xylosus*, *S. simulans*, *S. lugdunensis*, *S. schleiferi* and *S. warneri* strains (Fig. 5).

Example 6 : Multiplex amplification of *femA* and *mecA* genetic determinants for a molecular diagnosis of a specific staphylococcal infection

A total of 48 patients treated in 4 contiguous intensive cares ,units were included in the study. Endotracheal aspirates (ETA) were collected from the patients and submitted to the multiplex PCR analysis according to the technique described by Vannuffel et al. (1995). Clinical specimens were homogenised in 5 ml of TE buffer (20 mM TRIS HCl, pH 8.0, 10 mM EDTA) containing 2% (w/v) SDS.

The homogenate (1.5 ml) was then centrifuged for 5 minutes at 7500 xg. The cellular pellet was washed once with TE buffer lysed in the presence of 1% (v/v) Triton X-100 and 50 µg of lysostaphin (Sigma) and incubated for 15 minutes at 37 °C. Lysis was completed by adding 100 µg of proteinase K (Boehringer). The lysate was incubated for another 5 minutes at 55 °C and 5 minutes at 95 °C, and centrifuged at 4000 xg for 5 minutes.

In order to purify bacterial DNA, 200 µl of supernatant were then filtered on a Macherey-Nagel Nucleospin C+T® column and eluted with 200 µl sterile H_2O. Two different amounts of DNA suspension (2 µl and 200 µl) were submitted to multiplex PCR amplification with the primers 5'-TGGCTATCGTGTCACAATCG-3' and 5'-

CTGGAACTTGTTGAGCAGAG-3' for *mecA* and the above-described primers for *femA*, yielding different fragments.

femA and *mecA* signals were found in specimens containing either susceptible *S. aureus* (n = 10) and methycillin-resistant coagulase-negative *Staphylococci* (n = 6) respectively. On the other hand, no signal was obtained from ETA gram-negative bacteria (n = 5) as well as MS-CNS (n = 6) and from 5 ETA containing normal pharyngeal flora.

This multiplex PCR strategy for detecting *Staphylococci* in ETA was completed in less than 6 hours either on the day of the samples' collection. This is an advantage with respect to the time required to conventional identification and susceptibility tests (48 to 72 hours).

Example 7 : Amplification, cloning and sequencing of other *femA* genes

Two primers were selected among the conserved parts of the consensus sequence for the amplification of the *femA* gene.

These primers are *femS1*, *femS2* and *femAS1* (anti-sense primer). ADN from strains of *Staphylococcus hominis*, *saprophyticus*, *haemolyticus*, *lugdunensis*, *schleiferi*, *sciuri*, *xylosus*, *simulans*, *capitis*, *gallinarum*, *cohnii* and *warneri* were amplified from said primers and amplification fragments were cloned in the vector pCR®-XLTOPO and introduced by electroporation in *E. coli* cells TOP10 (TOPO XL PCR Cloning Kit®, Invitrogen, Carlsbad, CA).

Amplified fragments of strain *S. lugdunensis*, *schleiferi*, *sciuri*, *xylosus*, and *capitis* were sequenced by Taq Dye Deoxy Terminator Cycle® sequencing on a ABI 277 DNA

sequencer® (PE Applied Biosystems, Foster City, CA) by the following primers :

femS1 or *femS2* or *femAS1*

fsq1S and *fsq1AS*

fsq2S and *fsq2AS*

fsq3S and *fsq3AS*

fsq4S and *fsq4AS*

fsq5S and *fsq5AS*

fsq6S and *fsq6AS*



REFERENCES

1. Alborn W.E. Jr et al., Gene 180 : 177-81 (1996)
2. Berger-Bächi B. et al, Mol Gen Genet 219 : 263-9 (1989)
3. Berger-Bächi B. et al., Antimicrob. Agents Chemother. 36 : 1367-73 (1992)
4. Chackbart et al., Antimicrobial Agent Chemotherapy 33 : 991-999 (1989)
5. de Lancastre H. et al., Antimicrob. Agents Chemother. 38 : 2590-8 (1994)
6. Hiramatsu K. et al., FEBS Letters 298 : 133-6 (1992)
7. Hurlimann-Dalel R.L. et al., Antimicrob. Agents Chemother. 36 : 6+17-21 (1992)
8. Kizaki M. et al., J. Hosp. Infect. 28 : 287-95 (1994)
9. Kleeman K.T. et al., J. Clin. Microbiol. 31 : 1318-1321 (1993)
10. Refshal K. et al., J. Hosp. Infect. 22(1) : 19-31 (1992)
11. Ryffel C. et al., Gene 94 : 137-8 (1990)
12. Ryffel C. et al., Antimicrob. Agents Chemother. 38 : 724-8 (1994)
13. Rupp M.E. et al., Clin. Infectious Diseases 19 : 231-245 (1994)
14. Stranden A.L. et al., J. Bacteriol. 179 : 9-16 (1997)
15. Suzuki E. et al., Antimicrob. Agents Chemother. 36 : 429-34 (1992)
16. Unal S. et al., J. Clin. Microb. 30 : 1685-1691 (1992)
17. Vannuffel P. et al., J. Clin. Microb. 33 : 2864-2867 (1995)
18. Vannuffel . et al., J. Clin. Microb. 36 : 2366-2368 (1998)

CLAIMS

1. Oligonucleotide for the specific identification of *Staphylococci* species which nucleotide sequence has between 15 and 45 base pairs, preferably between 15 and 25 base pairs, and which presents more than 60% homology with the "consensus" *femA* nucleotide sequence (CNS) of Fig. 3.

2. Oligonucleotide according to claim 1 for the specific identification of *Staphylococci* species, which nucleotide sequence has between 15 and 45 base pairs, preferably between 17 and 25 base pairs, and which presents more than 70% homology with the "consensus" *femA* nucleotide sequence (CNS) of Fig. 3.

3. Oligonucleotide according to claim 1 or 2 for the specific identification of *Staphylococci* species, which nucleotide sequence has between 15 and 45 base pairs, preferably between 17 and 25 base pairs, and which presents more than 80% homology with the "consensus" *femA* nucleotide sequence (CNS) of Fig. 3.

4. Oligonucleotide according to any of the claims 1 to 3 for the specific identification of *Staphylococci* species, which nucleotide sequence has between 15 and 45 base pairs, preferably between 17 and 25 base pairs, and which presents more than 90% homology with the "consensus" *femA* nucleotide sequence (CNS) of Fig. 3.

5. Oligonucleotide according to any of the preceding claims, which is selected from the group consisting of the following nucleotide sequences :

- ANAATGAANTTTACNAATTTNACNGCNANAGANTT

  and more particularly TAATGAAGTTTACAAAATTT or TAATGAAGTTTACNAAATTT

- ATGNCNNANAGNCATTTNACNCANA
  and more particularly TGCCATATAGTCATTTACGC
- TAGTNGGNATNAANAANAANNATAANGANGTNATTGC
- GTNCCNGTNATGAAANTNTTNAANTANTTTTATTC
- AATGCNGGNNANGATTGG
- GNAANNGNAANACNAAAAAAGTNNANAANAATGGNGTNAAAGT
  and more particularly AAAAAGTTCAAAAAATGG and AAAAAGTACAAAAAATGG
- AAGANGANNTNCCNATNTTNNGNTCATTNATGGANGATAC
- TATATNNANTTTGATGANTA
- AANGANATNGANAAANGNCCNGANAANAAAAA
  and more particularly AAAGATATTGAAAAACGA, AAAGATATTGAAAAGAGACC, AAAGATATCGAGAAAGAC and AAAGACATCGACAAGCGT.
- ANCATGGNAANGAATTACCNAT
  and more particularly GAACATGGTAATGAATTAC
- AATCCNTNTGAAGTNGTNTANTANGCNGGTGG
- AGNTATGCNNTNCAATGGNNNATGATTAANTATGC
- TTTANNGANGANGCNGAAGATGNNGGNGTNNTNAANTTNAAAAA
  and more particularly TTTACTGAAGATGCTGAAGA
- GTTGGNGANTTNNTNAAACC
  and more particularly GTTGGTGACTTTATTAAACC
- ATGAAATTTACAGAGTTAA

6. Oligonucleotide for the specific identification of *Staphylococci* species which nucleotide sequence has between 15 and 350 base pairs, preferably between 17 and 250 base pairs, and which presents less than 50% homology with the "consensus" *femA* nucleotide sequence (CNS) of Fig. 3.

7. Oligonucleotide according to claim 6 for the specific identification of *Staphylococci* species which nucleotide sequence has between 15 and 350 base pairs,

preferably between 17 and 250 base pairs, and which presents less than 40% homology with the "consensus" *femA* nucleotide sequence (CNS) of Fig. 3.

8. Oligonucleotide according to claim 6 or 7 for the specific identification of *Staphylococci* species which nucleotide sequence has between 15 and 350 base pairs, preferably between 17 and 250 base pairs, and which presents less than 30% homology with the "consensus" *femA* nucleotide sequence (CNS) of Fig. 3.

9. Oligonucleotide according to any of the claims 6 to 8 for the specific identification of *Staphylococci* species which nucleotide sequence has between 15 and 350 base pairs, preferably between 17 and 250 base pairs, and which presents less than 20% homology with the "consensus" *femA* nucleotide sequence (CNS) of Fig. 3.

10. Oligonucleotide according to claim 6, being a primer which nucleotide sequence has between 15 and 45 base pairs, preferably between 17 and 25 base pairs.

11. Oligonucleotide according to claim 10, which is selected from the group consisting of the following nucleotide sequences :

- ACAGCAGATGACATCATT
- TAATGAAAGAAATGTGCTTA
- ACACAACTTCAATTAGAAC
- AGTATTAGCAAATGCGG
- ATGCATATTTTCCGTAA
- CAGCAGATGACATCATT
- CATCTAAAGATATATTAAATGGA
- AGTATTAGCAAATGCGGGTCAC
- CAACACAACTTCAATTAGAA

12. Identification and/or quantification method of a *Staphylococci* species, which may present resistance to antibiotics and which is present in a sample, said method comprising the steps of :

- obtaining a nucleotide sequence from a *Staphylococci* species present in the sample,
- amplifying said nucleotide sequence with one or more oligonucleotide(s) according to the claims 1 to 8, and
- identifying and possibly quantifying the specific *Staphylococci* species :
  - by reverse hybridisation of the amplified nucleotide sequence with one or more oligonucleotide(s) according to the claims 9 to 11 which is (are) specific of said *Staphylococci* species and is (are) immobilised on a solid support or
  - by a comparative measure of the length of the amplified nucleotide sequence.

13. Diagnostic device for the identification of *Staphylococci* species comprising the oligonucleotide according to any of the preceding claims 1 to 11 and possibly all the media necessary for the identification of an amplified sequence of said *Staphylococci* species through any one of the methods selected from the group consisting of in situ hybridisation, hybridisation on a solid support, in solution on dot blot, Northern blot, Southern blot, probe hybridisation by the use of an isotopic or non-isotopic label, genetic amplification or a mixture thereof.

14. *femA* genetic sequence which presents more than 90% homology with a nucleotide or amino acid sequence selected from the group consisting of the nucleotide or

amino acid sequences represented in the enclosed Fig. 6 to 13.

15. Genetic sequence according to claim 14, being the nucleotide sequence of Fig. 6.

16. Genetic sequence according to claim 14, being the amino acid sequence of Fig. 6.

17. Genetic sequence according to claim 14, being the nucleotide sequence of Fig. 7.

18. Genetic sequence according to claim 14, being the amino acid sequence, of Fig. 7.

19. Genetic sequence according to claim 14, being the nucleotide sequence of Fig. 8.

20. Genetic sequence according to claim 14, being the amino acid sequence of Fig. 8.

21. Genetic sequence according to claim 14, being the nucleotide sequence of Fig. 9.

22. Genetic sequence according to claim 14, being the amino acid sequence of Fig. 9.

23. Genetic sequence according to claim 14, being the nucleotide sequence of Fig. 10.

24. Genetic sequence according to claim 14, being the amino acid sequence of Fig. 10.

25. Genetic sequence according to claim 14, being the nucleotide sequence of Fig. 11.

26. Genetic sequence according to claim 14, being the amino acid sequence of Fig. 11.

27.Genetic sequence according to claim 14, being the nucleotide sequence of Fig. 12.

28. Genetic sequence according to claim 14, being the amino acid sequence of Fig. 12.

29.Genetic sequence according to claim 14, being the nucleotide sequence of Fig. 13.

30. Genetic sequence according to claim 14, being the amino acid sequence of Fig. 13.



Oligonucleotides

femX1	TTCMAATCGCGGTCCAGT	213-230
femX2	CAAGAACATGGCAACGAATTACC	913-935
femX3	TGGGTAATTCGTTGCCATGTTCT	937-915
femX4	CCAAGCATCTTCAGCATCTTC	1133-1113
femX5	TTCTTTAACTGTTAACTCTGTAAATTTCA	1309-1281
femX6	ACATATTTACTTAATTCGTTAAAGAA	290-265
femX7	CAGAAAAATGGTGTTAAAGTAAGATTT	559-585
femX8	AAGAAATCTTACTT TCACACCATTTTT	588-562
femX9	AACTCGAAAATAGAACTA	(-43)-(-26)

FIG. 1

SUBSTITUTE SHEET (RULE 26)

```
S. haemolyticus     ---------- ----t----- -g-----a-- ---a--a--t -c---g--tg -caat-a--- a--taag--- c-at-t--t- ----c--a-- a-tgact-aa
S. hominis          aggagttata gag-t----- -g-----a-- ---a--a--t -c---a--tg -cgat-t--- t--aaaa--- c-at-t--c- ----t--a-- g-tgact-aa
S. aureus           aataggagta atg-t----- -g-----a-- ---a--a--t -a---g--tg -tgcc-t--- a--tagc--- c-at-c--t- ----c--g-- a-ctgtt-gc
S. epidermidis      gggagttatg aag-t----- -g-----g-- ---g--a--t -a---a--ta -tgac-t--- t--tcgt--- a-at-t--t- ----t--a-- a-tggaa-gt
S. saprophyticus    aggagtatat aaa-a----- -a-----g-- ---a--t--a -a---g--cg -tgca-t--- g--taaa--- c-ga-t--t- ----t--g-- a-tggtt-ga
      CONSENSUS     ---------- ---A-AATGA A-TTTAC-AA TTT-AC-GC- A-AGA-TT-- G----T-TAC -GA----ATG -C--A-AG-C ATTT-AC-CA -A-----G--100

S. haemolyticus     a-c--t--ga -g--ag---- aa-taaaaca --aa-t--ct ----t--t-- a--a--t--a g----t--g- -t-----a-- c--ca-gt-g --a--a--a-
S. hominis          a-t--t--gt -a--ag---- tg-gaaaact --aa-t--tt ----a--a-- t--a--t--a g----t--a- -c-----t-- t--ta-gc-a --t--t--a-
S. aureus           c-c--t--gt -a--gc---- tg-aggttat --aa-a--tt ----g--a-- a--a--c--t a----c--g- -c-----a-- t--ct-ac-t --t--t--a-
S. epidermidis      a-t--c--at -a--gg---- tg-aggtacc --gt-a--tt ----t--a-- t--a--t--t g----c--a- -g-----a-- t--tt-at-a --a--t--t-
S. saprophyticus    a-t--t--at -g--aa---- ag-aagtaca --aa-a--cc ----a--t-- t--g--t--t g----t--a- -a-----a-- a--tt-ac-t --a--t--t-
      CONSENSUS     -A-TA-GA-- T-AA--TTGC --A------- GA--C-CA-- TAGT-GG-AT -AA-AA-AA- -ATAA-GA-G T-ATTGC-GC -TG--T--T- AC-GC-GT-C200

S. haemolyticus     -a--c----- -t-t--t--g --c------- -t--cc-a-- a--t--a--t ----a-g-t- -tag---g-- t--t--c-tt --------t- -g--aaca--
S. hominis          -c--t----- -a-t--t--a --t------- -a--tc-t-- t--a--c--t ----a-g-a- -caa---a-- c--t--c-tt --------c- -a--aagt--
S. aureus           -t--t----- -g-g--c--g --t------- -a--tc-c-- t--a--g--t ----a-g-a- -tca---a-- c--a--c-tt --------t- -a--atca--
S. epidermidis      -t--a----- -a-a--t--a --t------- -c--tc-c-- t--a--a--a ----a-a-t- -taa---g-- t--a--t-tt --------t- -a--gagt--
S. saprophyticus    -t--t----- -t-c--c--g --t------- -c--ta-a-- t--a--c--a ----t-g-a- -taa---a-- c--a--t-ac --------c- -a--agca--
      CONSENSUS     C-GT-ATGAA A-T-TT-AA- TA-TTTTATT C-AA--G-GG -CC-GT-AT- GATT-T-A-A A---AGA-CT -GT-CA-T-- TTCTTTAA-G A-TT----AA300

S. haemolyticus     g---t-a--- c-gc-taa-t gtc----tg- tcgag-t--c --t--tt-ac -a-------- ttta------ --t--t--aa -taca-gt-- ---t--ta-t
S. hominis          a---t-a--- c-ac-aca-t gtt----tg- acgta-a--c --t--tt-gc -t-------- tcgt------ --t--t--ta -taca-ga-- ---t--ga-t
S. aureus           a---g-t--- a-ac-tcg-t gtc----cc- acata-c--t --a--tt-ac -a-------- cttg------ --t--c--ga -taca-gt-- ---t--ta-t
S. epidermidis      a---g-a--- a-at-taa-t gtt----tt- aagag-t--c --a--cc-tc -a-------- ttta------ --g--a--aa -aact-ga-- ---a--tc-t
S. saprophyticus    a---g-a--- a-ac-taa-g cct----tt- acgag-a--t --t--tc-tg -t-------- tcgt------ --t--t--ag -atta-ca-- ---g--tc-c
      CONSENSUS     -TAT-T-AAA -A--A---T- ---TATA--T -----T-GA- CC-TA--T-- C-TATCAATA ----AATCAT GA-GG-GA-- T----G--AA TGC-GG--A-400

S. haemolyticus     ------t-c- -t---a-ga- gaagcatc-c --a-t-g-a- -tgaa--c-- tact-aa--t -----t--ga -taaa----- cc-a-at--t --t--tt--g
S. hominis          ------t-c- -c---a-aa- gaaacaat-a --a-a-c-a- -cgaa--g-- taca-ca--a -----t--aa -atta----- tc-g-tc--t --a--tt--a
S. aureus           ------t-c- -t---a-aa- gagtaact-a --a-t-g-a- -tact--a-- ccat-aa--a -----t--tg -gcta----- tc-t-at--c --a--gt--g
S. epidermidis      ------a-t- -t---g-at- agagagtt-a --a-a-a-a- -cgaa--a-- ccac-aa--a -----t--tg -atta----- cc-a-at--t --t--tc--a
S. saprophyticus    ------a-t- -t---a-aa- gaaacaac-c --t-a-a-g- -tgaa--t-- ttta-ct--c -----c--aa -actt----- aa-a-tc--t --t--tt--g
      CONSENSUS     GATTGG-T-T T-GAT-A--T --------T- GG-T-T-A-C A----GG-TT ----A--GG- TTTGA-CC-- T----CAAAT --G-T--CA- TC-GT--TA-500

S. haemolyticus     -----aaaaa t----cat-t a-a--ta-at -a--tgga-- ----a-tc-a c-t--ac-t- -t--t----- ---tc-a--a -----t--g- ----taag--
S. hominis          -----aagga t----ctg-t a-a--tg-at -a--tgga-- ----a-tt-a c-a--aa-a- -t--t----- ---cc-a--a -----t--t- ----aaga--
S. aureus           -----aaaga t----cag-a g-t--ca-ca -t--aaat-- ----g-ac-t a-a--aa-a- -c--g----- ---ta-a--g -----t--t- ----aaga--
S. epidermidis      -----gcaaa c----gtg-t a-t--tg-tt -a--aaac-- ----g-tt-a a-a--gc-t- -t--t----- ---ta-g--a -----a--t- ----ccgc--
S. saprophyticus    -----gctgg a----ctg-t a-a--cg-ac -t--tggt-- ----a-tt-a c-t--ac-a- -t--t----- ---ac-g--a -----t--g- ----aaga--
      CONSENSUS     ATTTA----- -AAAA---C- -A-GA--T-- T-AA----AT GGAT-G--T- -G-AA--G-A A-AC-AAAAA AGT--A-AA- AATGG-GT-A AAGT----TT600

S. haemolyticus     ct-atcag-- --a--ac-t- -a--c--cc- t-----t--- --a-----aa -c--aa-g-- a-aa--ccaa ---a-a--t- -tagt--c-- t--t--tc-c
S. hominis          tc-tacta-- --a--at-a- -t--t--ca- a-----t--- --a-----at -a--ga-t-- a-aa--ttct ---a-a--g- -tagt--t-- c--t--tc-a
S. aureus           tt-atctg-- --a--ac-a- -a--t--ta- a-----t--- --a-----gt -a--at-a-- a-ct--tgct ---c-t--t- -caaa--t-- c--c--tc-c
S. epidermidis      tt-atctg-- --a--gt-a- -t--a--ta- g-----t--- --g-----ct -t--aa-t-- a-at--tgca ---a-a--a- -tagt--t-- t--c--ca-a
S. saprophyticus    tt-aggtg-- --t--gt-g- -a--a--cc- c-----c--- --a-----tt -t--aa-a-- g-at--tgac ---a-a--t- -cgat--t-- t--t--ta-g
      CONSENSUS     --T-----AA GA-GA--T-C C-AT-TT--G -TCATT-ATG GA-GATAC-- C-GA--C-AA -G--TT---- GAT-G-GA-G A----TT-TA -TA-AA--G-700
```

FIG2a

SUBSTITUTE SHEET (RULE 26)

FIG.2b

```
S. haemolyticus   -atagac--- tc-----tca c--gc-t--a --ac-a--t- ----ta-g-- ------g--c a-cgaa---t -ac-aaat-- ac-tg-aact t-a-a-----
S. hominis        -ttgatc--- tt-----tag a--at-a--a --tc-c--a- ----aa-a-- ------a--t c-tgaa---c -tc-tgca-- ac-tc-gaca t-a-a-----
S. aureus         -taaaat--- ac-----ccg t--gt-a--a --tt-a--g- ----ca-c-- ------a--t a-taaa---c -aa-cgaa-- gc-tg-tatt t-a-a-----
S. epidermidis    -tcaaac--- at-----ccg t--tt-a--a --ac-a--c- ----ta-c-- ------g--t a-agag---c -aa-taat-- aa-aa-tgtg c-t-a-----
S. saprophyticus  -taagat--- at-----tcg t--gc-t--c --at-a--t- ----gg-t-- ------a--t a-aaca---t -aa-ggct-- ac-cg-agta t-a-g-----
      CONSENSUS   T------ATT --AAAGA--- -GT--T-GT- CC--T-GC-T ATAT--A-TT TGATGA-TA- -T----GAA- T--A----GA --G--A---- -T-A-TAAAG 800

                  801
S. haemolyticus   -tgtt--t-- ---tt-a--a --t--t--a- --c-a--a-- c--t-----g --attt--t- -aaaagaa-- tc-tg--a-a ---t-agat- -c--tc-a--
S. hominis        -ctta--c-- ---tc-a--a --t--t--a- --c-a--a-- t--c-----a --acaa--t- -aaaaata-- tt-ag--c-g ---t-aaaa- -a--tg-g--
S. aureus         -ttta--t-- ---gt-a--g --t--t--a- --c-t--t-- a--t-----a --acat--c- -gcgagat-- ct-ac--c-a ---c-tgat- -a--tg-g--
S. epidermidis    -ttat--t-- ---tt-a--a --c--t--g- --c-t--a-- g--t-----a --acat--c- -aaaggaa-- tt-ag--c-a ---c-cgat- -a--tc-g--
S. saprophyticus  -tata--t-- ---ag-t--g --t--a--a- --a-a--a-- a--t-----a --gtat--t- -aaaagaa-- tt-ag--c-a ---c-gatt- -a--cc-a--
      CONSENSUS   A----AA-AA AGC--T-AA- GA-AT-GA-A AA-G-CC-GA -AA-AAAAA- GC----AA-A A-------AA --T--AA-A- CAA-T----G C-AA--A-CA 900

                  901
S. haemolyticus   ---at-ag-c --g-ct-aaa aat-ac--gc cg-a-----t --t------- -a--t--a-- a-gt-t---c t-t--t---- -a-t------ t--t--t--t
S. hominis        ---aa-tg-t --a-ca-cac aac-tc--tt ag-a-----t --c------- -a--a--t-- t-ga-t---c t-t--t---- -a-t------ t--a--t--t
S. aureus         ---ga-tg-a --a-gt-aac gtc-ac--ga ag-a-----t --t------- -t--c--t-- t-gt-t---c t-t--c---- -a-t------ t--t--t--t
S. epidermidis    ---aa-ta-t --a-ct-aaa act-aa--ca ag-a-----c --t------- -c--c--t-- t-gc-t---t a-a--t---- -g-t------ a--t--c--c
S. saprophyticus  ---aa-ag-t --a-cc-ctg cgt-ac--ga ga-g-----t --c------- -g--t--t-- a-ct-a---t a-t--t---- -t-a------ c--t--c--t
      CONSENSUS   AAA--T--A- GA-G--A--- ---T--AA-- --A-CATGG- AA-GAATTAC C-AT-TC-GC -G--T-CTT- -T-AT-AATC C-T-TGAAGT -GT-TA-TA- 1000

                  1001
S. haemolyticus   --a-----a- -t--t---aa a-ata-a--t --t--a--c- -t-----ta- t------aca --------c- ----aa-tg- t---ggt--t g-ta-a--c-
S. hominis        --a-----a- -g--a---aa a-ata-a--c --c--t--a- -t-----ag- t------act --------t- ----aa-tg- t---ggc--t g-cc-t--t-
S. aureus         --t-----t- -a--a---gc a-tcc-t--t --t--c--a- -t-----ag- g------gaa --------t- ----at-aa- t---ggc--t g-cc-t--t-
S. epidermidis    --t-----a- -t--a---cg t-atc-c--t --t--a--g- -c-----gg- t------aag --------c- ----aa-tg- a---ggt--t a-tc-g--t-
S. saprophyticus  --a-----t- -a--t---ga a-tta-a--t --t--t--t- -t-----aa- a------aag --------t- ----ta-ag- t---aat--a g-ta-a--t-
      CONSENSUS   GC-GGTGG-A C-TC-AAT-- -T---G-CA- TT-GC-GG-A G-TATGC--T -CAATGG--- ATGATTAA-T ATGC--T--A -CAT---AT- -A--G-TA-A 1100

                  1101
S. haemolyticus   ----c----- ta----c--- a-t----gt- -a--c--t-- -----tt--a --ca-t--a- -t-----a-- t-tca----a --cg-aa-t- -g--t-----
S. hominis        ----t----- ga----t--- c-t----ca- -t--t--t-- -----ca--t --tg-a--a- -t-----a-- a-tta----a --tg-aa-t- -a--t-----
S. aureus         ----c----- tg----t--- a-a----ca- -a--t--t-- -----ct--t --ag-t--a- -c-----a-- t-aca----t --aa-ta-t- -a--t-----
S. epidermidis    ----c----- ta----t--- g-c----gt- -a--t--t-- -----ct--c --ag-t--g- -t-----g-- c-atg----c --tg-ta-a- -a--c-----
S. saprophyticus  ----t----- ta----t--- c-t----ct- -a--t--a-- -----ca--t --tg-t--a- -t-----a-- t-tta----a --tg-ag-a- -a--t-----
      CONSENSUS   ATTT-TATGG --TTAG-GGT -A-TTTA--G A-GA-GC-GA AGATG--GG- GT--T-AA-T T-AAAAA-GG -T---ATGC- GA--T--T-G A-TA-GTTGG 1200

                  1201
S. haemolyticus   a--c--tg-g -----t--t- -c--a--tt- g--ttcagtg ----aga--c -c-----ga- ta-aaaa-ga tttaat--aa g-ggggaat- gacg-atatg
S. hominis        t--t--cg-t -----t--a- -t--a--aa- g--ttcacta ----caa--c -t-----aa- ta-aaag-ga ttgaat--ag a-ggggaat- gtga-a----
S. aureus         t--c--ta-t -----a--t- -t--a--tg- t--cgcagca ----ccg--c -t-----ag- ta-agac-ga attttt--gg a-gggaatt- tcaa-ac---
S. epidermidis    t--c--ta-t -----t--t- -t--a--aa- g--taacatt ----gaa--c -t-----ac- ..-aaga-at agattt--ag a-gggaatt- tcta-tt---
S. saprophyticus  t--t--ta-t -----g--t- -t--g--aa- g--caaaatt ----cga--t -g-----aa- ta-ggat-aa aagaaa--aa c-taaatag- agag-actaa
      CONSENSUS   -GA-TT--T- AAACC-AT-A A-AA-CC--T -TA------- TATA---CA- T-AAAAA--T --A----A-- ------TA-- -A-------A ----A----- 1300

                  1301                    1329
S. haemolyticus   ------atga aatttacag agttaaac
S. hominis        ---------- --------- -------
S. aureus         ------atga aatttacag agttaacct
S. epidermidis    ------atga aatttacag agttaaca
S. saprophyticus  gctagaatga aatttacag agttaac
      CONSENSUS   ------ATGA AATTTACAG AGTTAA---
```

NNNNNNNNNN NNNANAATGA ANTTTACNAA TTTNACNGCN ANAGANTTNN GNNNNTNTAC NGANNNNATG NCNNANAGNC ATTTNACNCA NANNNNNGNN
NANTANGANN TNAANNTTGC NNANNNNNNN GANNCNCANN TAGTNGGNAT NAANAANAAN NATAANGANG TNATTGCNGC NTGNNTNNTN ACNGCNGTNC
CNGTNATGAA ANTNTTNAAN TANTTTTATT CNAANNGNGG NCCNGTNATN GATTNTNANA ANNNAGANCT NGTNCANTNN TTCTTTAANG ANTTNNNNAA
NTATNTNAAA NANNANNNTN NNNTATANNT NNNNNTNGAN CCNTANNTNN CNTATCAATA NNNNAATCAT GANGGNGANN TNNNNGNNAA TGCNGGNNAN
GATTGGNTNT TNGATNANNT NNNNNNNNTN GGNTNTNANC ANNNNGGNTT NNNNANNGGN TTTGANCCNN TNNNNCAAAT NNGNTNNCAN TCNGTNNTAN
ATTTANNNNN NAAAANNNCN NANGANNTNN TNAANNNNAT GGATNGNNTN NGNAANNGNA ANACNAAAAA AGTNNANAAN AATGGNGTNA AAGTNNNNTT
NNTNNNNNAA GANGANNTNC CNATNTTNNG NTCATTNATG GANGATACNN CNGANNCNAA NGNNTTNNNN GATNGNGANG ANNNNTTNTA NTANAANNGN
TNNNNNNATT NNAAAGANNN NGTNNTNGTN CCNNTNGCNT ATATNNANTT TGATGANTAN NTNNNNGAAN TNNANNNNGA NNGNNANNNN NTNANTAAAG
ANNNNAANAA AGCNNTNAAN GANATNGANA AANGNCCNGA NAANAAAAAN GCNNNNAANA ANNNNNNNAA NNTNNAANAN CAANTNNNNG CNAANNANCA
AAANNTNNAN GANGNNANNN NNNTNNAANN NNANCATGGN AANGAATTAC CNATNTCNGC NGNNTNCTTN NTNATNAATC CNTNTGAAGT NGTNTANTAN
GCNGGTGGNA CNTCNAATNN NTNNNGNCAN TTNGCNGGNA GNTATGCNNT NCAATGGNNN ATGATTAANT ATGCNNTNNA NCATNNNATN NANNGNTANA
ATTTNTATGG NNTTAGNGGT NANTTTANNG ANGANGCNGA AGATGNNGGN GTNNTNAANT TNAAAAANGG NTNNNATGCN GANNTNNTNG ANTANGTTGG
NGANTTNNTN AAACCNATNA ANAANCCNNT NTANNNNNNN TATANNNCAN TNAAAAANNT NNANNNNANN NNNNNNTANN NANNNNNNNA NNNNANNNNN
NNNNNNATGA AATTTACAG AGTTAANNN

FIG.3 CONSENSUS SEQUENCE

220 bases	*S.aureus*	*S.epidermidis*	*S. hominis*
S.aureus	-	-	-
S.epidermidis	17.7	-	-
S.hominis	13.2	16.8	-
S.saprophyticus	17.3	18.6	16.8

Base % (non appariated) between the primers bioU1 and bioU3

FIG4a



FIG.4b

1 : mecA

2: femA Sau

3. femA Sep

4. femA Sho

5. femA Ssa



FIG.5

AMPLIFICATION of CNS SPECIES under UNIVERSAL CONDITIONS.

(1) : S. haemolyticus
(2) : S. capitis
(3) : S. cohnii Th(reaction PCR) = 48°C
(4) : S. xylosus
(5) : S. simulans
(6) : S. lugdunensis
(7) : S. schleiferi
(8) : S. warneri

S. haemolyticus FIG.6a

```
        10                  30                  50
        .                   .                   .
ATAATGAAGTTTACAAATTTAACAGCTACAGAGTTTGGCAATTATACAGATAAGATGCCA
   MetLysPheThrAsnLeuThrAlaThrGluPheGlyAsnTyrThrAspLysMetPro

        70                  90                  110
        .                   .                   .
TATAGTCATTTCACACAAATGACTGAAAACTATGAGATGAAAGTTGCAAATAAAACAGAA
TyrSerHisPheThrGlnMetThrGluAsnTyrGluMetLysValAlaAsnLysThrGlu

        130                 150                 170
        .                   .                   .
ACTCACTTAGTTGGTATAAAAAATAAAGATAATGAGGTTATTGCAGCCTGCATGTTGACA
ThrHisLeuValGlyIleLysAsnLysAspAsnGluValIleAlaAlaCysMetLeuThr

        190                 210                 230
        .                   .                   .
GCAGTACCAGTCATGAAATTTTTTAAGTACTTTTATTCTAACCGAGGACCTGTAATTGAT
AlaValProValMetLysPhePheLysTyrPheTyrSerAsnArgGlyProValIleAsp

        250                 270                 290
        .                   .                   .
TATGATAATAGAGAGCTTGTTCACTTTTTCTTTAATGAGTTAACAAAGTATTTAAAACAG
TyrAspAsnArgGluLeuValHisPhePhePheAsnGluLeuThrLysTyrLeuLysGln

        310                 330                 350
        .                   .                   .
CATAATTGTCTATATGTTCGAGTTGACCCTTATTTACCATATCAATATTTAAATCATGAT
HisAsnCysLeuTyrValArgValAspProTyrLeuProTyrGlnTyrLeuAsnHisAsp

        370                 390                 410
        .                   .                   .
GGTGAAATTACAGGTAATGCTGGTAATGATTGGTTCTTTGATAAGATGAAGCATCTCGGA
GlyGluIleThrGlyAsnAlaGlyAsnAspTrpPhePheAspLysMetLysHisLeuGly

        430                 450                 470
        .                   .                   .
TTTGAACATGAAGGCTTTACTAAAGGTTTTGATCCGATTAAACAAATCCGATATCATTCT
PheGluHisGluGlyPheThrLysGlyPheAspProIleLysGlnIleArgTyrHisSer

        490                 510                 530
        .                   .                   .
GTTTTAGATTTAAAAAATAAAACATCTAAAGATATATTAAATGGAATGGATAGTCTACGT
ValLeuAspLeuLysAsnLysThrSerLysAspIleLeuAsnGlyMetAspSerLeuArg

        550                 570                 590
        .                   .                   .
AAACGTAATACTAAAAAAGTTCAAAAAAATGGTGTGAAAGTTAAGTTCTTATCAGAAGAA
LysArgAsnThrLysLysValGlnLysAsnGlyValLysValLysPheLeuSerGluGlu

        610                 630                 650
        .                   .                   .
GAACTTCCAATCTTCCGTTCATTTATGGAAGATACAACCGAAACGAAAGAATTCCAAGAT
GluLeuProIlePheArgSerPheMetGluAspThrThrGluThrLysGluPheGlnAsp

        670                 690                 710
        .                   .                   .
AGAGATGATAGTTTCTATTATAATCGCTATAGACATTTCAAAGATCACGTGCTTGTACCA
ArgAspAspSerPheTyrTyrAsnArgTyrArgHisPheLysAspHisValLeuValPro
```

```
       730                 750                 770
        .         .         .         .         .         .
CTAGCTTATATTAAGTTTGATGAGTACATCGAAGAATTACAAAATGAACGTGAAACTTTA
LeuAlaTyrIleLysPheAspGluTyrIleGluGluLeuGlnAsnGluArgGluThrLeu

       790                 810                 830
        .         .         .         .         .         .
AATAAAGATGTTAATAAAGCTTTAAAAGATATTGAAAAACGACCAGACAATAAAAAGGCA
AsnLysAspValAsnLysAlaLeuLysAspIleGluLysArgProAspAsnLysLysAla

       850                 870                 890
        .         .         .         .         .         .
TTTAATAAAAAAGAAAATCTTGAAAAACAATTAGATGCCAATCAACAAAAATTAGACGAG
PheAsnLysLysGluAsnLeuGluLysGlnLeuAspAlaAsnGlnGlnLysLeuAspGlu

       910                 930                 950
        .         .         .         .         .         .
GCTAAAAAATTACAAGCCGAACATGGTAATGAATTACCAATTTCAGCAGGTTTCTTCTTT
AlaLysLysLeuGlnAlaGluHisGlyAsnGluLeuProIleSerAlaGlyPhePhePhe

       970                 990                1010
        .         .         .         .         .         .
ATTAATCCATTTGAAGTTGTTTATTATGCAGGTGGAACTTCTAATAAATATAGACATTTT
IleAsnProPheGluValValTyrTyrAlaGlyGlyThrSerAsnLysTyrArgHisPhe

      1030                1050                1070
        .         .         .         .         .         .
GCAGGCAGTTATGCTATTCAATGGACAATGATTAACTATGCAATTGATCATGGTATTGAT
AlaGlySerTyrAlaIleGlnTrpThrMetIleAsnTyrAlaIleAspHisGlyIleAsp

      1090                1110                1130
        .         .         .         .         .         .
AGATACAATTTCTATGGTATTAGCGGTAATTTTAGTGAAGACGCTGAAGATGTTGGAGTC
ArgTyrAsnPheTyrGlyIleSerGlyAsnPheSerGluAspAlaGluAspValGlyVal

      1150                1170                1190
        .         .         .         .         .         .
ATTAAATTTAAAAAAGGTTTCAATGCAGACGTAATTGAGTATGTTGGAGACTTTGTGAAA
IleLysPheLysLysGlyPheAsnAlaAspValIleGluTyrValGlyAspPheValLys

      1210                1230                1250
        .         .         .         .         .         .
CCTATTAACAAACCTTTGTATTCAGTGTATAAGACACTCAAAAAGATTAAAAAAAGATTT
ProIleAsnLysProLeuTyrSerValTyrLysThrLeuLysLysIleLysLysArgPhe

      1270                1290
        .         .         .         .
AATTAAAGAGGGGAATAGACGAATATGAAATTTACAGAGTTAAAC
AsnEndArgGlyGluEndThrAsnMetLysPheThrGluLeuAsn
```

FIG.6b

S. lugdunensis FIG.7a

```
        10                  30                  50
        .         .         .         .         .         .
ACAGCAAATGAATTCGGTGATTTCACAGATCAAATGCCATATAGTCATTTTACTCAAATG
ThrAlaAsnGluPheGlyAspPheThrAspGlnMetProTyrSerHisPheThrGlnMet

        70                  90                  110
        .         .         .         .         .         .
ACAGGTAACTATAATTTAAAAGTTGCCGAAAAAACAGAAACACATTTAGTTGGTGTTAAA
ThrGlyAsnTyrAsnLeuLysValAlaGluLysThrGluThrHisLeuValGlyValLys

       130                 150                 170
        .         .         .         .         .         .
AATAATAATAACGAAGTAATTGCAGCATGTTTATTGACAGCTGTACCAGTCATGAAGTTT
AsnAsnAsnAsnGluValIleAlaAlaCysLeuLeuThrAlaValProValMetLysPhe

       190                 210                 230
        .         .         .         .         .         .
TTTAAATACTTTTACAGCAATAGAGGCCCAGTTATAGATTATGCTAACCAAGAACTTGTA
PheLysTyrPheTyrSerAsnArgGlyProValIleAspTyrAlaAsnGlnGluLeuVal

       250                 270                 290
        .         .         .         .         .         .
CATTTTTTCTTTAATGAGCTAACTAAATATTTAAAAAAGTATAACTGTCTCTATGTCCGC
HisPhePhePheAsnGluLeuThrLysTyrLeuLysLysTyrAsnCysLeuTyrValArg

       310                 330                 350
        .         .         .         .         .         .
ATAGATCCATACTTACCTTATCAATATAGAGACCATGACGGTAATATAACGGCAAATGCT
IleAspProTyrLeuProTyrGlnTyrArgAspHisAspGlyAsnIleThrAlaAsnAla

       370                 390                 410
        .         .         .         .         .         .
GGCAATGATTGGTTTTTCAATAAAATGGAACAACTCGGATACCATCATGATGGCTTTACA
GlyAsnAspTrpPhePheAsnLysMetGluGlnLeuGlyTyrHisHisAspGlyPheThr

       430                 450                 470
        .         .         .         .         .         .
ACAGGATTTGATCCAATATTACAAATCAGATTCCATTCTATTCTTAATTTAAAGGATAAG
ThrGlyPheAspProIleLeuGlnIleArgPheHisSerIleLeuAsnLeuLysAspLys

       490                 510                 530
        .         .         .         .         .         .
ACAGCTAAAGATGTTTTAAATAATATGGATAGTTTACGTAAAAGAAATACCAAAAAAAGT
ThrAlaLysAspValLeuAsnAsnMetAspSerLeuArgLysArgAsnThrLysLysSer

       550                 570                 590
        .         .         .         .         .         .
TCAAAAAATGGAGTCAAAGTAAAGTTCCTTACTGAAGAAGAACTACCTATCTTTCGTTCA
SerLysAsnGlyValLysValLysPheLeuThrGluGluGluLeuProIlePheArgSer

       610                 630                 650
        .         .         .         .         .         .
TTTATGGAGCAGACGTCAGAATCTAAAGAATTCTCTGATAGAGACGACCAATTTTATTAC
PheMetGluGlnThrSerGluSerLysGluPheSerAspArgAspAspGlnPheTyrTyr

       670                 690                 710
        .         .         .         .         .         .
AATCGGTTTAAGTACTATAAAGATAGGGTGCTTGTGCCTCTAGCATATTTAAAATTTGAT
AsnArgPheLysTyrTyrLysAspArgValLeuValProLeuAlaTyrLeuLysPheAsp
```

```
       730                 750                 770
        .         .         .         .         .         .
GAATATATAGAAGAACTAACGAATGAACGACAAACTTTAGAAAAAGATTTAGGCAAAGCA
GluTyrIleGluGluLeuThrAsnGluArgGlnThrLeuGluLysAspLeuGlyLysAla

       790                 810                 830
        .         .         .         .         .         .
CTTAAAGACATTGAGAAACGACCAGATAACAAAAAAGCTTATAATAAACGAGACAACCTA
LeuLysAspIleGluLysArgProAspAsnLysLysAlaTyrAsnLysArgAspAsnLeu

       850                 870                 890
        .         .         .         .         .         .
CAACAACAACTCGATGCCAATCAACAAAAGTTAAATGAGGCTAATCAGTTACAAGCGGAA
GlnGlnGlnLeuAspAlaAsnGlnGlnLysLeuAsnGluAlaAsnGlnLeuGlnAlaGlu

       910                 930                 950
        .         .         .         .         .         .
CACGGTAATGAGTTACCTATCTCTGCCGGTTTCTTTATTATTAATCCGTTTGAAGTTGTA
HisGlyAsnGluLeuProIleSerAlaGlyPhePheIleIleAsnProPheGluValVal

       970                 990                 1010
        .         .         .         .         .         .
TACTACGCTGGAGGTACCGCTAATAAATATCGTCATTTTGCAGGTAGTTACGCGGTTCAG
TyrTyrAlaGlyGlyThrAlaAsnLysTyrArgHisPheAlaGlySerTyrAlaValGln

      1030                1050                1070
        .         .         .         .         .         .
TGGACTATGATTAACTATGCTATCGAACACGGCATAGACAGATATAATTTCTACGGCATT
TrpThrMetIleAsnTyrAlaIleGluHisGlyIleAspArgTyrAsnPheTyrGlyIle

      1090                1110                1130
        .         .         .         .         .         .
AGTGGAAACTTCTCAGATGATGCTGAAGACGCAGGTGTCATTCGCTTTAAAAAAGGTTAT
SerGlyAsnPheSerAspAspAlaGluAspAlaGlyValIleArgPheLysLysGlyTyr

      1150                1170                1190
        .         .         .         .         .         .
GGTGCAGAAGTGATTGAATACGTTGGTGATTTTGTAAAACCTATAAATAAACCTATGTAT
GlyAlaGluValIleGluTyrValGlyAspPheValLysProIleAsnLysProMetTyr

      1210                1230                1250
        .         .         .         .         .         .
AAACTTTATTCAGTGTTAAAACGAATTCAAAATAAGCTATAGAGGAGAATGGATTAATTA
LysLeuTyrSerValLeuLysArgIleGlnAsnLysLeuEndArgArgMetAspEndLeu

      1270
        .         .
TGAAATTTACAGAGTTTAAC
EndAsnLeuGlnSerLeu
```

FIG.7b

S. xylosus FIG.8a

```
        10                  30                  50
         .         .         .         .         .         .
ACGCAAAAGAGTTTGGGTGCATTTTCAGATAAAATGCCAAATAGCCATTTCACGCAAATG
ThrGlnLysSerLeuGlyAlaPheSerAspLysMetProAsnSerHisPheThrGlnMet

        70                  90                  110
         .         .         .         .         .         .
GTAGGGAATTATGAATTGAAAATTGCAGAAAGTACTGAAACACATTTAGTAGGTATAAAA
ValGlyAsnTyrGluLeuLysIleAlaGluSerThrGluThrHisLeuValGlyIleLys

        130                 150                 170
         .         .         .         .         .         .
AACAATGATAATGAAGTCATTGCAGCTTGTTTATTAACTGCAGTACCAGTAATGAAATTC
AsnAsnAspAsnGluValIleAlaAlaCysLeuLeuThrAlaValProValMetLysPhe

        190                 210                 230
         .         .         .         .         .         .
TTTAAGTATTTTTATACTAATAGAGGTCCGGTTATAGATTTTGAAAATAAAGAATTAGTG
PheLysTyrPheTyrThrAsnArgGlyProValIleAspPheGluAsnLysGluLeuVal

        250                 270                 290
         .         .         .         .         .         .
CATTACTTTTTCAATGAACTATCTAAATATGTGAAAAAACATAATGCGCTTTATTTAAGA
HisTyrPhePheAsnGluLeuSerLysTyrValLysLysHisAsnAlaLeuTyrLeuArg

        310                 330                 350
         .         .         .         .         .         .
GTTGATCCTTATTTAGCATATCAATACCGTAATCATGATGGTGAGGTATTGGAAAATGCA
ValAspProTyrLeuAlaTyrGlnTyrArgAsnHisAspGlyGluValLeuGluAsnAla

        370                 390                 410
         .         .         .         .         .         .
GGACATGATTGGATTTTCGATAAAATGAAGCAGCTTGGATATAAACACCAAGGATTTTTA
GlyHisAspTrpIlePheAspLysMetLysGlnLeuGlyTyrLysHisGlnGlyPheLeu

        430                 450                 470
         .         .         .         .         .         .
ACTGGTTTCGATTCAATTATTCAAATTAGGTTCCACTCTGTACTGGATTTAGTAGGTAAA
ThrGlyPheAspSerIleIleGlnIleArgPheHisSerValLeuAspLeuValGlyLys

        490                 510                 530
         .         .         .         .         .         .
ACTGCTAAAGATGTACTAAATGGTATGGATAGTTTACGTAAACGTAATACTAAAAAAGTA
ThrAlaLysAspValLeuAsnGlyMetAspSerLeuArgLysArgAsnThrLysLysVal

        550                 570                 590
         .         .         .         .         .         .
CAAAAAAATGGCGTGAAAGTAAGGTTCTTAAGGGAAGATGAGTTGCCAATTTTCCGTTCA
GlnLysAsnGlyValLysValArgPheLeuArgGluAspGluLeuProIlePheArgSer

        610                 630                 650
         .         .         .         .         .         .
TTCATGGAAGATACATCTGAAACTAAAGACTTTGACGATAGAGACGATGGCTTTTACTAC
PheMetGluAspThrSerGluThrLysAspPheAspAspArgAspAspGlyPheTyrTyr

        670                 690                 710
         .         .         .         .         .         .
AATAGATTAAGGTATTATAAAGATCGCGTATTAGTACCTCTAGCTTATATGGATTTCAAT
AsnArgLeuArgTyrTyrLysAspArgValLeuValProLeuAlaTyrMetAspPheAsn
```

```
       730                 750                 770
        .                   .                   .                   .
GAATATATTGAAGAATTGCAAGCTGAACGTGAGGTGTTAAGCAAAGATATCAATAAAGCA
GluTyrIleGluGluLeuGlnAlaGluArgGluValLeuSerLysAspIleAsnLysAla

       790                 810                 830
        .                   .                   .                   .
GTAAAAGATATCGAGAAAAGACCTGAAAATAAAAAAGCATATAATAAAAAAGATAATCTA
ValLysAspIleGluLysArgProGluAsnLysLysAlaTyrAsnLysLysAspAsnLeu

       850                 870                 890
        .                   .                   .                   .
GAGAAACAACTTATAGCGAATCAACAAAAAATTGATGAAGCTAAAACTCTACAAGAGAAG
GluLysGlnLeuIleAlaAsnGlnGlnLysIleAspGluAlaLysThrLeuGlnGluLys

       910                 930                 950
        .                   .                   .                   .
CATGGTAACGAACTACCAATCTCAGCAGCATATTTCATCATTAACCCTTATGAAGTAGTG
HisGlyAsnGluLeuProIleSerAlaAlaTyrPheIleIleAsnProTyrGluValVal

       970                 990                 1010
        .                   .                   .                   .
TATTATGCGGGTGGAACGTCAAATGAGTTTAGACATTTTGCTGGTAGTTATGCCATTCAA
TyrTyrAlaGlyGlyThrSerAsnGluPheArgHisPheAlaGlySerTyrAlaIleGln

      1030                1050                1070
        .                   .                   .                   .
TGGAAGATGATTAACTATGCTATTGACCATAATATTGATAGATATAATTTTTATGGAATT
TrpLysMetIleAsnTyrAlaIleAspHisAsnIleAspArgTyrAsnPheTyrGlyIle

      1090                1110                1130
        .                   .                   .                   .
AGTGGTCATTTTACAGAAGATGCAGAAGATGCCGGTGTAGTTAAATTTAAAAAAGGATTT
SerGlyHisPheThrGluAspAlaGluAspAlaGlyValValLysPheLysLysGlyPhe

      1150                1170                1190
        .                   .                   .                   .
AATGCGGATGTAGTGGAATATGTTGGTGATTTTATTAAACCAATCAATAAACCAATGTAC
AsnAlaAspValValGluTyrValGlyAspPheIleLysProIleAsnLysProMetTyr

      1210                1230                1250
        .                   .                   .                   .
AAAATTTATACGACATTAAAGAAAATTAAAGATAAAAAGAAATAAACATTTAATAGAAGG
LysIleTyrThrThrLeuLysLysIleLysAspLysLysLysEndThrPheAsnArgArg

      1270                1290
        .                   .                   .
GAACTAAGCTAGAATGAAATTTACAGAGTTAAACC
GluLeuSerEndAsnGluIleTyrArgValLys
```

FIG.8b

S. capitis FIG.9a

```
        10                  30                  50
        .                   .                   .
ACAGCTAAAGAATTTAGTGACTTTACTGATCAAATGCCTTATAGCCATTTTACTCAGATG
ThrAlaLysGluPheSerAspPheThrAspGlnMetProTyrSerHisPheThrGlnMet

        70                  90                  110
        .                   .                   .
GAAGGTAATTATGAACTTAAAGTTGCTGAAGGTACGGATTCACATCTCGTAGGAATTAAA
GluGlyAsnTyrGluLeuLysValAlaGluGlyThrAspSerHisLeuValGlyIleLys

       130                 150                 170
        .                   .                   .
AATAATGACAACCAAGTGATTGCAGCATGTTTATTAACTGCTGTACCTGTAATGAAAATT
AsnAsnAspAsnGlnValIleAlaAlaCysLeuLeuThrAlaValProValMetLysIle

       190                 210                 230
        .                   .                   .
TTTAAATATTTTTACTCAAATCGCGGGCCAGTGATTGATTATGATAATAAAGAGCTTGTT
PheLysTyrPheTyrSerAsnArgGlyProValIleAspTyrAspAsnLysGluLeuVal

       250                 270                 290
        .                   .                   .
CACTTTTTCTTTAATGAATTAAGTAAATATGTAAAAAAGCATAATTGTCTTTATCTAAGA
HisPhePhePheAsnGluLeuSerLysTyrValLysLysHisAsnCysLeuTyrLeuArg

       310                 330                 350
        .                   .                   .
GTTGACCCTTATCTTCCTTATCAATACTTAAATCATGACGGTGAAATTATTGGAAATGCT
ValAspProTyrLeuProTyrGlnTyrLeuAsnHisAspGlyGluIleIleGlyAsnAla

       370                 390                 410
        .                   .                   .
GGCCATGATTGGTTTTTCAATAAGATGGAAGAATTAGGATTTGAACATGAAGGCTTTCAT
GlyHisAspTrpPhePheAsnLysMetGluGluLeuGlyPheGluHisGluGlyPheHis

       430                 450                 470
        .                   .                   .
AAAGGCTTCCATCCTATCTTACAAGTAAGATATCATTCAGTTTTAGATTTAAAAGATAAA
LysGlyPheHisProIleLeuGlnValArgTyrHisSerValLeuAspLeuLysAspLys

       490                 510                 530
        .                   .                   .
ACGGCTAAAGATGTACTCAAAGGAATGGATAGTTTAAGAAAGCGTAATACTAAGAAAGTA
ThrAlaLysAspValLeuLysGlyMetAspSerLeuArgLysArgAsnThrLysLysVal

       550                 570                 590
        .                   .                   .
CAAAAAAATGGTGTCAAAGTCCGTTTCCTATCCGAAGATGAATTACCTATCTTTAGATCA
GlnLysAsnGlyValLysValArgPheLeuSerGluAspGluLeuProIlePheArgSer

       610                 630                 650
        .                   .                   .
TTTATGGAAGATACTACAGAAACGAAAGAGTTCGCCGATAGAGATGATAGTTTCTATTAT
PheMetGluAspThrThrGluThrLysGluPheAlaAspArgAspAspSerPheTyrTyr
```

```
      670                 690                 710
       .                   .                   .                   .
AATCGATTAAAATACTTTAAAGATAGAGTATTAGTACCATTAGCATATGTTGACTTCGAT
AsnArgLeuLysTyrPheLysAspArgValLeuValProLeuAlaTyrValAspPheAsp

      730                 750                 770
       .                   .                   .                   .
GAGTATATTGAAGAACTTAATAATGAAAGAGATGTTCTTAATAAAGATTTAAATAAGGCG
GluTyrIleGluGluLeuAsnAsnGluArgAspValLeuAsnLysAspLeuAsnLysAla

      790                 810                 830
       .                   .                   .                   .
CTCAAAGATATTGAGAAGAGACCTGATAATAAGAAAGCTTATAACAAAAGAGATAATCTT
LeuLysAspIleGluLysArgProAspAsnLysLysAlaTyrAsnLysArgAspAsnLeu

      850                 870                 890
       .                   .                   .                   .
CAACAACAATTAGATGCAAATCAACAAAAAATTGATGAAGCTAAAAACTTACAACAAGAA
GlnGlnGlnLeuAspAlaAsnGlnGlnLysIleAspGluAlaLysAsnLeuGlnGlnGlu

      910                 930                 950
       .                   .                   .                   .
CATGGTAATGAATTACCTATTTCAGCTGGATATTTCTTCATTAATCCGTTTGAAGTTGTT
HisGlyAsnGluLeuProIleSerAlaGlyTyrPhePheIleAsnProPheGluValVal

      970                 990                1010
       .                   .                   .                   .
TATTACGCAGGTGGCACATCGAATCGTTATCGTCACTATGCCGGAAGTTATGCAATTCAA
TyrTyrAlaGlyGlyThrSerAsnArgTyrArgHisTyrAlaGlySerTyrAlaIleGln

     1030                1050                1070
       .                   .                   .                   .
TGGAAAATGATAAACTATGCTTTAGAACATGGAATTAACCGTTATAATTTTTATGGAGTT
TrpLysMetIleAsnTyrAlaLeuGluHisGlyIleAsnArgTyrAsnPheTyrGlyVal

     1090                1110                1130
       .                   .                   .                   .
AGTGGGGACTTCAGTGAAGACGCTGAAGATGTAGGAGTAATTAAGTTCAAAAAAGGCTAT
SerGlyAspPheSerGluAspAlaGluAspValGlyValIleLysPheLysLysGlyTyr

     1150                1170                1190
       .                   .                   .                   .
AATGCTGATGTTATTGAATATGTAGGTGATTTTATCAAGCCAATCAATAAACCTATGTAT
AsnAlaAspValIleGluTyrValGlyAspPheIleLysProIleAsnLysProMetTyr

     1210                1230                1250
       .                   .                   .                   .
GCAATCTATAACGCACTTAAAAAGTTAAAGAAATAGATTTTTTTACCAACCCAATTATCT
AlaIleTyrAsnAlaLeuLysLysLeuLysLysEndIlePheLeuProThrGlnLeuSer

     1270
       .                   .
AATTATGAAATTTACAGAGTTAA
AsnTyrGluIleTyrArgVal
```

FIG.9b

S. schleiferi

FIG.10a

```
        10                  30                  50
         .                   .                   .                   .
ACGACGGCTGAATTTGGTGCGTTTACAGATCAAATGCCATATAGCCATTTCACGCAAATG
ThrThrAlaGluPheGlyAlaPheThrAspGlnMetProTyrSerHisPheThrGlnMet

        70                  90                  110
         .                   .                   .                   .
GTAGGGAACTATGAATTAAAGGTTGCTGAAGGTGTTGAAACACATCTTGTCGGCATTAAA
ValGlyAsnTyrGluLeuLysValAlaGluGlyValGluThrHisLeuValGlyIleLys

       130                 150                 170
         .                   .                   .                   .
GATAACAACAATAACGTACTAGCAGCATGTTTACTGACAGCAGTGCCAGTAATGAAGTTT
AspAsnAsnAsnAsnValLeuAlaAlaCysLeuLeuThrAlaValProValMetLysPhe

       190                 210                 230
         .                   .                   .                   .
TTTAAATATTTTTATTCAAACCGCGGACCAGTCATGGACTACGAAAATAAAGAGCTCGTT
PheLysTyrPheTyrSerAsnArgGlyProValMetAspTyrGluAsnLysGluLeuVal

       250                 270                 290
         .                   .                   .                   .
CATTTCTTTTTTAATGAACTTTCAAAATATGTTAAGAAATATCACGCATTGTATTTGAGA
HisPhePhePheAsnGluLeuSerLysTyrValLysLysTyrHisAlaLeuTyrLeuArg

       310                 330                 350
         .                   .                   .                   .
GTAGACCCTTATTTACCAATGTTAAAGCGAAACCATGATGGTGAAGTGATTGAAAGATAC
ValAspProTyrLeuProMetLeuLysArgAsnHisAspGlyGluValIleGluArgTyr

       370                 390                 410
         .                   .                   .                   .
GGCAGTGACTGGTTTTTTGATAAAATGGCTGAATTAAACTTTGAACATGAAGGTTTCACA
GlySerAspTrpPhePheAspLysMetAlaGluLeuAsnPheGluHisGluGlyPheThr

       430                 450                 470
         .                   .                   .                   .
ACTGGGTTTGATACAATAAGGCAAATTCGTTTTCATTCTGTGCTCGATGTTGAAAATAAA
ThrGlyPheAspThrIleArgGlnIleArgPheHisSerValLeuAspValGluAsnLys

       490                 510                 530
         .                   .                   .                   .
ACATCAAAAGACATCTTAAATCAAATGGATAATTTAAGGAAAAGAAATACGAAAAAAGTA
ThrSerLysAspIleLeuAsnGlnMetAspAsnLeuArgLysArgAsnThrLysLysVal

       550                 570                 590
         .                   .                   .                   .
CAGAAAAATGGTGTGAAAGTCCGCTATCTAAACGAAGATGAATTACATATTTTCCGTTCG
GlnLysAsnGlyValLysValArgTyrLeuAsnGluAspGluLeuHisIlePheArgSer

       610                 630                 650
         .                   .                   .                   .
TTTATGGAAGATACATCTGAAACAAAAGATTTTGTAGATAGAGATGACGATTTTTATTAT
PheMetGluAspThrSerGluThrLysAspPheValAspArgAspAspAspPheTyrTyr

       670                 690                 710
         .                   .                   .                   .
CATCGTATGAAATACTATAAAGATCGTGTCCGCGTACCACTAGCGTATATTGATTTTAAT
HisArgMetLysTyrTyrLysAspArgValArgValProLeuAlaTyrIleAspPheAsn
```

```
      730                 750                 770
       .                   .                   .                   .                   .                   .
GCATATTTAGCAGAGCTCAACACTGAAGCGCAAGACTTTAAAAAAGAAATTGCAAAAGCA
AlaTyrLeuAlaGluLeuAsnThrGluAlaGlnAspPheLysLysGluIleAlaLysAla

      790                 810                 830
       .                   .                   .                   .                   .                   .
GATAAAGACATCGACAAGCGTCCTGAAAATCAGAAAGCCATAAATAAAAAGAAAAATTTA
AspLysAspIleAspLysArgProGluAsnGlnLysAlaIleAsnLysLysLysAsnLeu

      850                 870                 890
       .                   .                   .                   .                   .                   .
GAGCAACAACTAGAAGCGAATCAAGCTAAAATAAAAGAAGCAGAAACATTGCAACTTAAA
GluGlnGlnLeuGluAlaAsnGlnAlaLysIleLysGluAlaGluThrLeuGlnLeuLys

      910                 930                 950
       .                   .                   .                   .                   .                   .
CACGGTGACACATTACCGATTTCGGCTGGATTCTTTATTATTAATCCATTTGAGGTTGTT
HisGlyAspThrLeuProIleSerAlaGlyPhePheIleIleAsnProPheGluValVal

      970                 990                 1010
       .                   .                   .                   .                   .                   .
TATTATGCAGGCGGCACAGCAAACGAATTTCGTCATTTTGCTGGAAGCTACGCAGTGCAA
TyrTyrAlaGlyGlyThrAlaAsnGluPheArgHisPheAlaGlySerTyrAlaValGln

      1030                1050                1070
       .                   .                   .                   .                   .                   .
TGGGAAATGATTAATTATGCGATTGATTATCAAATTCCAAGATATAACTTTTATGGCATT
TrpGluMetIleAsnTyrAlaIleAspTyrGlnIleProArgTyrAsnPheTyrGlyIle

      1090                1110                1130
       .                   .                   .                   .                   .                   .
AGTGGTGATTTTTCAGAAGATGCAGAAGATGCAGGTGTGATAAAATTTAAAAAAGGCTAT
SerGlyAspPheSerGluAspAlaGluAspAlaGlyValIleLysPheLysLysGlyTyr

      1150                1170                1190
       .                   .                   .                   .                   .                   .
AATGCAGAAGTAATAGAATATGTCGGTGATTTTATTAAGCCTATAAACAAACCTGCCTAT
AsnAlaGluValIleGluTyrValGlyAspPheIleLysProIleAsnLysProAlaTyr

      1210                1230                1250
       .                   .                   .                   .                   .                   .
ACAGTCTACTTAAAATTAAAGCAATTAAAAGACAAGATAAAAAGATAAGATATAGCAAAG
ThrValTyrLeuLysLeuLysGlnLeuLysAspLysIleLysArgEndAspIleAlaLys

      1270                1290
       .                   .                   .
AGAAGGGATTTATTGGTATGAAATTTACAGAGTTAA
ArgArgGlyPheIleGlyMetLysPheThrGluLeu
```

FIG.10b

S. sciuri

FIG.11a

```
         10                  30                  50
         .                   .                   .
ACACTGGAATTTGAAGCTTTTACAAATAAAATGCCGTACGCGCATTTTACACAAGCAGTA
ThrLeuGluPheGluAlaPheThrAsnLysMetProTyrAlaHisPheThrGlnAlaVal

         70                  90                  110
         .                   .                   .
GGTAATTATGAATTAAAAACATCTGAAGGTACTTCAACACATTTAGTAGGGGTCAAAGAT
GlyAsnTyrGluLeuLysThrSerGluGlyThrSerThrHisLeuValGlyValLysAsp

         130                 150                 170
         .                   .                   .
AATCAAGGTGAAGTATTAGCTGCGTGTCTGTTAACAAGTGTACCAGTTATGAAGAAATTT
AsnGlnGlyGluValLeuAlaAlaCysLeuLeuThrSerValProValMetLysLysPhe

         190                 210                 230
         .                   .                   .
AATTACTTTTACTCAAATAGAGGACCAGTAATGGATTATGACAACAAAGAACTTGTTGAC
AsnTyrPheTyrSerAsnArgGlyProValMetAspTyrAspAsnLysGluLeuValAsp

         250                 270                 290
         .                   .                   .
TTTTTCTTTAAAGAAATCGTGAGCTATTTAAAAAGTTATAAAGGATTATTCTTTAGAATC
PhePhePheLysGluIleValSerTyrLeuLysSerTyrLysGlyLeuPhePheArgIle

         310                 330                 350
         .                   .                   .
GATCCTTACTTGCCATATCAACTAAGAGATCATGATGGCAATATTAAAAAATCATTCAAC
AspProTyrLeuProTyrGlnLeuArgAspHisAspGlyAsnIleLysLysSerPheAsn

         370                 390                 410
         .                   .                   .
CGTGATGGTTTAATTAAACAATTTGAATCATTAGGTTATGAACACCAAGGCTTCACAACT
ArgAspGlyLeuIleLysGlnPheGluSerLeuGlyTyrGluHisGlnGlyPheThrThr

         430                 450                 470
         .                   .                   .
GGTTTCCACCCAATACATCAAATTAGATGGCATTCTGTACTTGATTTAGAAAGTATGGAC
GlyPheHisProIleHisGlnIleArgTrpHisSerValLeuAspLeuGluSerMetAsp

         490                 510                 530
         .                   .                   .
GAAAAGACGCTCATCAAGAACATGGACAGTTTAAGAAAAAGAAATACTAAAAAAGTTCAA
GluLysThrLeuIleLysAsnMetAspSerLeuArgLysArgAsnThrLysLysValGln

         550                 570                 590
         .                   .                   .
AAAAATGGTGTTAAAGTTCGTTTTCTATCTAAAGATGAAATGCCGATATTCCGTCAATTT
LysAsnGlyValLysValArgPheLeuSerLysAspGluMetProIlePheArgGlnPhe

         610                 630                 650
         .                   .                   .
ATGGAAGATACTACAGAGAAGAAAGATTTCAACGATCGTGGCGATGACTTCTATTACAAT
MetGluAspThrThrGluLysLysAspPheAsnAspArgGlyAspAspPheTyrTyrAsn
```

```
       670                 690                 710
        .         .         .         .         .         .
AGATTAAAATACTTTGAAAATGTAAAGATTCCTTTAGCATATATAGACTTTGAAACTTAC
ArgLeuLysTyrPheGluAsnValLysIleProLeuAlaTyrIleAspPheGluThrTyr

       730                 750                 770
        .         .         .         .         .         .
ATTCCACAATTAGAAAAAGAACATGAACAATACAACAAAGATATTGCAAAAGCTGAAAAA
IleProGlnLeuGluLysGluHisGluGlnTyrAsnLysAspIleAlaLysAlaGluLys

       790                 810                 830
        .         .         .         .         .         .
GATTTAGAAAAGAAACCAGATAATCAAAAAACGATTAATAAAATAGACAACTTAAAACAA
AspLeuGluLysLysProAspAsnGlnLysThrIleAsnLysIleAspAsnLeuLysGln

       850                 870                 890
        .         .         .         .         .         .
CAAAGAGAAGCAAATGAAGCTAAATTAGAAGAAGCACTTCAACTACAACAAGAACATGGT
GlnArgGluAlaAsnGluAlaLysLeuGluGluAlaLeuGlnLeuGlnGlnGluHisGly

       910                 930                 950
        .         .         .         .         .         .
GATACATTACCAATAGCAGCTGGTTTCTTTATTATTAATCCATTTGAAGTTGTATATTAT
AspThrLeuProIleAlaAlaGlyPhePheIleIleAsnProPheGluValValTyrTyr

       970                 990                 1010
        .         .         .         .         .         .
GCAGGTGGTTCATCGAATGAATATCGTCACTTTGCAGGTAGTTATGCAATTCAGTGGGAA
AlaGlyGlySerSerAsnGluTyrArgHisPheAlaGlySerTyrAlaIleGlnTrpGlu

      1030                1050                1070
        .         .         .         .         .         .
ATGATTAAATACGCGTTAGATCACAACATTGACCGTTATAACTTCTATGGTATCAGCGGA
MetIleLysTyrAlaLeuAspHisAsnIleAspArgTyrAsnPheTyrGlyIleSerGly

      1090                1110                1130
        .         .         .         .         .         .
GACTTCTCAGAAGATGCACCTGATGTTGGCGTTATTAAATTTAAAAAAGGTTACAATGCA
AspPheSerGluAspAlaProAspValGlyValIleLysPheLysLysGlyTyrAsnAla

      1150                1170                1190
        .         .         .         .         .         .
GATGTTTATGAATATATTGGTGATTTCGTTAAACCAATTAATAAACCAGCGTACAAAGCA
AspValTyrGluTyrIleGlyAspPheValLysProIleAsnLysProAlaTyrLysAla

      1210                1230                1250
        .         .         .         .         .         .
TATACAACACTAAAAAAAGTATTAAAAAAATAAATGATTTTCAGTAAGAGAGGAATTTAG
TyrThrThrLeuLysLysValLeuLysLysEndMetIlePheSerLysArgGlyIleEnd

      1270
        .         .
ATAATATGAAATTTACAGAGTTAA
IleIleEndAsnLeuGlnSerEnd
```

FIG.11b

. ***Staphylococcus hominis***

```
                                                                                                    100
taaaattttaaaattagtcaactcaaattaaataaagattctaaattaggagttatagagataATGAAGTTTACAAATTTAACAGCTACAGAATTTGGCG
                                                                  M  K  F  T  N  L  T  A  T  E  F  G  D

                                                                                                    200
ATTTTACTGAAAAAATGCCATATAGCCATTTTACACAGATGACTGAAAATTATGAGTTAAAAGTTGCTGAGAAAACTGAAACTCATTTAGTAGGAATTAA
  F  T  E  K  M  P  Y  S  H  F  T  Q  M  T  E  N  Y  E  L  K  V  A  E  K  T  E  T  H  L  V  G  I  K

                                                                                                    300
AAATAAAGATAATGAAGTCATTGCTGCTTGTATGCTAACTGCTGTACCCGTTATGAAAATTTTTAAATATTTTTATTCAAATCGTGGTCCAGTCATTGAT
 N  K  D  N  E  V  I  A  A  C  M  L  T  A  V  P  V  M  K  I  F  K  Y  F  Y  S  N  R  G  P  V  I  D

                                                                                                    400
TATGAAAACAAAGAACTCGTTCACTTTTTCTTTAACGAATTAAGTAAATATTTAAAACAACAACATTGTTTATATGTACGTATAGACCCTTATTTGCCTT
Y  E  N  K  E  L  V  H  F  F  F  N  E  L  S  K  Y  L  K  Q  Q  H  C  L  Y  V  R  I  D  P  Y  L  P  Y

                                                                                                    500
ATCAATATCGTAATCATGATGGTGATATTACAGGAAATGCTGGGAATGATTGGTTCTTCGATAAAATGAAACAATTAGGATATCAACACGAAGGGTTTAC
  Q  Y  R  N  H  D  G  D  I  T  G  N  A  G  N  D  W  F  F  D  K  M  K  Q  L  G  Y  Q  H  E  G  F  T

                                                                                                    600
AACAGGATTTGATCCAATATTACAAATTCGGTTCCATTCAGTTTTAAATTTAAAGGATAAAACTGCTAAAGATGTATTAAATGGAATGGATAGTTTACGA
 T  G  F  D  P  I  L  Q  I  R  F  H  S  V  L  N  L  K  D  K  T  A  K  D  V  L  N  G  M  D  S  L  R

                                                                                                    700
AAAAGAAATACTAAAAAAGTCCAAAAAAATGGTGTTAAAGTAAGATTTCTTACTAAAGAAGAATTACCTATTTTCAGATCATTTATGGAAGATACATCAG
K  R  N  T  K  K  V  Q  K  N  G  V  K  V  R  F  L  T  K  E  E  L  P  I  F  R  S  F  M  E  D  T  S  E

                                                                                                    800
AGACTAAAGAATTTTCTGATAGAGAGGATAGTTTTTACTATAATCGATTTGATCATTTTAAAGATAGAGTATTAGTACCTCTCGCATATATAAAATTTGA
  T  K  E  F  S  D  R  E  D  S  F  Y  Y  N  R  F  D  H  F  K  D  R  V  L  V  P  L  A  Y  I  K  F  D

                                                                                                    900
TGAATATCTTGAAGAACTTCATGCAGAACGTCAGACATTAAATAAAGACTTAAACAAAGCTCTAAAAGATATTGAAAAACGACCAGATAACAAAAAAGCA
 E  Y  L  E  E  L  H  A  E  R  Q  T  L  N  K  D  L  N  K  A  L  K  D  I  E  K  R  P  D  N  K  K  A

                                                                                                   1000
CAAAATAAAAAAATAAATTTAGAACAGCAATTAAAAGCAAATGAGCAAAAAATTGATGAAGCAACACAACTTCAATTAGAACATGGTAACGAATTACCAA
Q  N  K  K  I  N  L  E  Q  Q  L  K  A  N  E  Q  K  I  D  E  A  T  Q  L  Q  L  E  H  G  N  E  L  P  I

                                                                                                   1100
TATCTGCTGGATTCTTCTTTATTAATCCATTTGAAGTTGTATATTATGCAGGTGGAACGTCAAATAAATATAGACACTTCGCTGGAAGTTATGCAGTTCA
  S  A  G  F  F  F  I  N  P  F  E  V  V  Y  Y  A  G  G  T  S  N  K  Y  R  H  F  A  G  S  Y  A  V  Q

                                                                                                   1200
ATGGACTATGATTAATTATGCAATTGATCATGGCATTGACCGTTATAATTTTTATGGGATTAGTGGTCATTTTACAGATGATGCTGAAGATGCAGGTGTT
 W  T  M  I  N  Y  A  I  D  H  G  I  D  R  Y  N  F  Y  G  I  S  G  H  F  T  D  D  A  E  D  A  G  V

                                                                                                   1300
GTAAAATTTAAAAAAGGATTTAATGCAGATGTAATTGAATATGTTGGTGATTTCGTTAAACCTATAAATAAACCAATGTATTCACTATATACAACACTTA
V  K  F  K  K  G  F  N  A  D  V  I  E  Y  V  G  D  F  V  K  P  I  N  K  P  M  Y  S  L  Y  T  T  L  K

AAAAAATTAAAAAGAGATTGAATTAAGaggggaatagtgagaa          1343
  K  I  K  K  R  L  N  ///
```

FIG.12

Staphylococcus saprophyticus

```
acttgtttagattagaattaaactcgaaaatagaactatagataaataggagtatataaaaaaATGAAATTTACGAATTTAACTGCAAAAGAGTTCGGTG    100
                                                                M  K  F  T  N  L  T  A  K  E  F  G  A

CATTTACGGATAAAATGCCGAATAGTCATTTTACGCAAATGGTTGGAAATTATGAATTGAAAATTGCAGAAAGTACAGAAACACACCTAGTAGGTATTAA    200
  F  T  D  K  M  P  N  S  H  F  T  Q  M  V  G  N  Y  E  L  K  I  A  E  S  T  E  T  H  L  V  G  I  K

GAATAATGATAATGAAGTAATTGCAGCATGTTTACTTACAGCTGTTCCTGTTATGAAATTCTTCAAGTATTTTTATTCCAATAGAGGTCCAGTCATAGAT    300
 N  N  D  N  E  V  I  A  A  C  L  L  T  A  V  P  V  M  K  F  F  K  Y  F  Y  S  N  R  G  P  V  I  D

TTTGAAAATAAAGAACTCGTACATTACTTCTTTAACGAATTAGCAAAATATGTAAAAAAACATAATGCCTTATATTTACGAGTAGATCCTTATCTTGCTT    400
F  E  N  K  E  L  V  H  Y  F  F  N  E  L  A  K  Y  V  K  K  H  N  A  L  Y  L  R  V  D  P  Y  L  A  Y

ATCAATATCGTAATCATGATGGTGAAGTATTAGCAAATGCGGGTCACGATTGGATTTTTGATAAAATGAAACAACTCGGTTATAAGCATGAAGGTTTTTT    500
  Q  Y  R  N  H  D  G  E  V  L  A  N  A  G  H  D  W  I  F  D  K  M  K  Q  L  G  Y  K  H  E  G  F  L

AACTGGCTTTGACCCAATACTTCAAATAAGATTCCATTCTGTTTTAGATTTAGCTGGAAAAACTGCTAAAGACGTACTTAATGGTATGGATAGTTTACGT    600
 T  G  F  D  P  I  L  Q  I  R  F  H  S  V  L  D  L  A  G  K  T  A  K  D  V  L  N  G  M  D  S  L  R

AAACGAAATACTAAAAAAGTACAGAAAAATGGTGTGAAAGTAAGATTTTTAGGTGAAGATGAGTTGCCAATATTCCGCTCATTCATGGAAGATACTTCTG    700
K  R  N  T  K  K  V  Q  K  N  G  V  K  V  R  F  L  G  E  D  E  L  P  I  F  R  S  F  M  E  D  T  S  E

AAACAAAGGATTTTGACGATAGAGATGACGATTTTTATTATAATAGGTTAAGATATTATAAAGATCGTGTGCTTGTCCCATTAGCTTATATGGATTTTGA    800
  T  K  D  F  D  D  R  D  D  D  F  Y  Y  N  R  L  R  Y  Y  K  D  R  V  L  V  P  L  A  Y  M  D  F  D

TGAATATATAACAGAATTAAAGGCTGAACGCGAAGTATTAAGTAAAGATATAAATAAAGCAGTTAAGGATATAGAAAAAAGACCAGAAAATAAAAAAGCG    900
 E  Y  I  T  E  L  K  A  E  R  E  V  L  S  K  D  I  N  K  A  V  K  D  I  E  K  R  P  E  N  K  K  A

TATAATAAAAAAGAAAATTTAGAACAACAACTGATTGCAAACCAACAAAAAATAGATGAAGCCACTGCGTTACAAGAGAAGCATGGTAACGAATTACCGA   1000
Y  N  K  K  E  N  L  E  Q  Q  L  I  A  N  Q  Q  K  I  D  E  A  T  A  L  Q  E  K  H  G  N  E  L  P  I

TTTCTGCAGCTTACTTTATTATTAATCCTTATGAAGTCGTTTACTATGCAGGTGGTACATCTAATGAATTTAGACATTTTGCTGGTAGTTATGCAATACA   1100
  S  A  A  Y  F  I  I  N  P  Y  E  V  V  Y  Y  A  G  G  T  S  N  E  F  R  H  F  A  G  S  Y  A  I  Q

ATGGAAGATGATTAATTATGCTATAGATCATAATATAGATAGATATAATTTTTATGGTATTAGTGGTCATTTTACTGAAGATGCAGAAGATGCAGGTGTT   1200
 W  K  M  I  N  Y  A  I  D  H  N  I  D  R  Y  N  F  Y  G  I  S  G  H  F  T  E  D  A  E  D  A  G  V

GTTAAATTTAAAAAAGGTTTTAATGCAGATGTAGTAGAATATGTTGGTGATTTTATTAAACCGATTAATAAGCCAATGTACAAAATTTATACGACATTGA   1300
V  K  F  K  K  G  F  N  A  D  V  V  E  Y  V  G  D  F  I  K  P  I  N  K  P  M  Y  K  I  Y  T  T  L  K

AAAAAATTAAGGATAAAAAGAAATAAacataaatagaagggaactaagctagaatgaaatttacagagtta                              1371
  K  I  K  D  K  K  K  ///
```

FIG.13

C 9/8 1 / C 1 /

European Patent Office

EUROPEAN SEARCH REPORT

Application Number
EP 00 87 0127

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X Y	WO 96 07917 A (NANOGEN) 14 March 1996 (1996-03-14) * the whole document *	17-20 1-16	C12Q1/68
Y	ARMOUR ET AL: "MEASUREMENT OF LOCUS COPY NUMBER BY HYBRIDISATION WITH AMPLIFIABLE PROBES" NUCLEIC ACIDS RESEARCH,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 28, no. 2, 2000, pages 605-609, XP002138423 ISSN: 0305-1048 * the whole document *	1-16	
Y	WO 98 11253 A (ERNEST ISABELLE ;REMACLE JOSE (BE); ALEXANDRE ISABELLE (BE); ZAMMA) 19 March 1998 (1998-03-19) * the whole document *	1-16	
Y	WO 93 25563 A (HOPE CITY ;WALLACE ROBERT BRUCE (US)) 23 December 1993 (1993-12-23) * the whole document *	1-16	TECHNICAL FIELDS SEARCHED (Int.Cl.7) C12Q
Y	WO 97 27317 A (CHEE MARK ;LAI CHAOQIANG (US); LEE DANNY (US); AFFYMETRIX INC (US)) 31 July 1997 (1997-07-31) * the whole document *	1-16	
Y	WO 97 31256 A (BLOK HERMAN ;BARANY GEORGE (US); KEMPE MARIA (US); ZIRVI MONIB (US) 28 August 1997 (1997-08-28) * the whole document *	1-16	
A	EP 0 420 260 A (HOFFMANN LA ROCHE) 3 April 1991 (1991-04-03) * the whole document *		

-/--

The present search report has been drawn up for all claims

Place of search	Date of completion of the search	Examiner
THE HAGUE	12 December 2000	Hagenmaier, S

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A : technological background
O : non-written disclosure
P : intermediate document

T : theory or principle underlying the invention
E : earlier patent document, but published on, or after the filing date
D : document cited in the application
L : document cited for other reasons

& : member of the same patent family, corresponding document

EPO FORM 1503 03.82 (P04C01)